Search

Your search keyword '"De Lazzari E."' showing total 191 results
Start Over Author "De Lazzari E."
191 results on '"De Lazzari E."'

2. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis

Author

Athan, E., Harris, O., Korman, T.M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C.Q., Garcia, P., Jones, S.B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M.P., Pafundi, P.C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F.E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M.F., Baban, T., Kanafani, Z.A., Kanj, S.S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D.R., Premru, M.M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Mària, C., Garcia-Gonzalez, J., Gatell, J.M., Marco, F., Miró, J.M., Moreno, A., Ortiz, J., Ninot, S., Paré, J.C., Pericas, J.M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J.M., Vidal, B., Vila, J., Bouza, E., Muñoz, P., Rodríguez-Créixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G.R., Reller, L.B., Fowler, V.G., Jr., Chu, V.H., Baloch, K., Dixon, C.C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L.P., Redick, T., Stafford, J., Anstrom, K., Bayer, A.S., Cabell, C.H., Karchmer, A.W., Sexton, D.J., Wang, A., Chu, V., Durack, D.T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Pericàs, J.M., Messina, J.A., Park, L., Sharma-Kuinkel, B.K., and Carugati, M.

Published
2017
Full Text
View/download PDF

3. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

Author

Palacio-Vieira, J, Reyes-Uruena, JM, Imaz, A, Bruguera, A, Force, L, Llaveria, AO, Llibre, JM, Vilaro, I, Borras, FH, Falco, V, Riera, M, Domingo, P, de Lazzari, E, Miro, JM, Casabona, J, Gurgui M., and Hernandez, J.

Subjects
Linkage, Cohort studies, HIV, Reengagement, Lost to follow-up
Abstract

Background Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. This scoping review is aimed at the description and analysis of the strategies used in high-income countries to reengage LTFU in HIV care, their implementation and impact. Methods A scoping review was done following Arksey & O ' Malley's methodological framework and recommendations from Joanna Briggs Institute. Peer reviewed articles were searched for in Pubmed, Scopus and Web of Science; and grey literature was searched for in Google and other sources of information. Documents were charted according to the information presented on LTFU, the reengagement procedures used in HIV units in high-income countries, published during the last 15 years. In addition, bibliographies of chosen articles were reviewed for additional articles. Results Twenty-eight documents were finally included, over 80% of them published in the United States later than 2015. Database searches, phone calls and/or mail contacts were the most common strategies used to locate and track LTFU, while motivational interviews and strengths-based techniques were used most often during reengagement visits. Outcomes like tracing activities efficacy, rates of reengagement and viral load reduction were reported as outcome measures. Conclusions This review shows a recent and growing trend in developing and implementing patient reengagement strategies in HIV care. However, most of these strategies have been implemented in the United States and little information is available for other high-income countries. The procedures used to trace and contact LTFU are similar across reviewed studies, but their impact and sustainability are widely different depending on the country studied.

Published
2021

4. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial

Author

Rojas, J, de Lazzari, E, Negredo, E, Domingo, P, Tiraboschi, J, Ribera, E, Abdulghani, N, Puig, J, Mateo, MG, Podzamczer, D, Gutierrez, MM, Paredes, R, Clotet, B, Gatell, JM, Blanco, JL, Martinez, E, and DOLAM Study Grp

Abstract

Background Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy. Methods DOLAM is a phase 4, randomised, open-label, non-inferiority trial, done at six HIV clinics in Catalonia, Spain. Adults with HIV-1 receiving a triple ART regimen, aged 18 years or older, with virological suppression, a CD4 nadir of at least 200 cells per ILL, who were HBsAg-negative, and without previous viral failure or resistance mutations to study drugs were eligible. Participants underwent computer-generated randomisation, stratified by the class of the third drug, and were assigned (1:1) to switch to oral dolutegravir 50 mg and lamivudine 300 mg once daily or to continue triple ART for 48 weeks. The primary endpoint was the proportion of people with an HIV RNA value of at least 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm, 8% non-inferiority margin). Both the primary and safety outcomes were evaluated in the intention-to-treat exposed population. The study is completed and was registered with EudraCT 201500027435. Findings Between July 7, 2015, and Oct 31, 2018, 265 participants were randomly assigned to switch to dolutegravir plus lamivudine (n=131) or to maintain triple ART (n=134) and all received at least one dose. Nine (7%) participants in the dual therapy group and ten (7%) in the triple therapy group were excluded before 48 weeks, mostly due to treatment discontinuations or virological failure. Participants were predominantly male (116 [87%] of 134 in the triple ART group and 111 [85%] of 131 in the dolutegravir plus lamivudine group). The difference in the proportion of participants with HIV RNA values of at least 50 copies per mL at 48 weeks between the dual therapy group (three [2%] of 131) and triple therapy group (two [1%] of 134) was 0middot8 percentage points (95% CI -3middot3 to 5middot2), showing non-inferiority of dolutegravir plus lamivudine dual therapy compared with triple ART. 73 (56%) of 131 participants allocated to dual therapy had 150 adverse effects, compared with 78 (58%) of 134 participants allocated to triple therapy who also had 150 adverse events (p=0middot68). Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. Interpretation Our findings show the efficacy and safety of dolutegravir plus lamivudine as a simplified therapy switch option for selected people with HIV with virological suppression on triple ART.

Published
2021

8. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

Author

Montoliu, A, Miro, JM, Domingo, P, Riera, M, Curran, A, Homar, F, Ambrosioni, J, Abdulghani, N, Force, L, Peraire, J, Vilaro, J, Masabeu, A, Orti, AJ, Dalmau, D, Casabona, J, Reyes, J, Bruguera, A, Muntada, E, Podzamczer, D, Llibre, JM, Navarro, G, Cortes, C, Falco, V, Mallolas, J, Manzardo, C, Imaz, A, Tiraboschi, J, Burgos, J, Mateo, MG, Gutierrez, MM, Murillas, J, Segura, F, Garcia-Gasalla, M, Puig, T, Vidal, F, Leon, E, Jaen, A, Almuedo, A, De Lazzari, E, Giralt, D, Martin, M, Gargoulas, F, Vanrell, T, Rubia, JC, Vila, J, Ferres, M, Morell, B, Tamayo, M, Laguno, M, Martinez, M, Blanco, JL, Garcia-Alcaide, F, Rojas, J, Martinez, E, Jou, A, Clotet, B, Saumoy, M, Silva, A, Prieto, P, Ribera, JNIE, Gurgui, M, Campins, AA, Fanjul, FJ, Leyes, M, Penaranda, M, Martin, L, Vilchez, H, Calzado, S, Cervantes, M, Amengual, MJ, Navarro, M, Payeras, T, Cifuentes, C, Comella, T, Vargas, M, Vilades, C, Barrufet, P, Chivite, I, Chamarro, E, Escrig, C, Cairo, M, Martinez-Lacasa, X, Font, R, Deig, E, Meyer, S, and Hernandez, J

Subjects
integrase strand transfer inhibitors, elvitegravir/cobicistat, neuropsychiatric toxicity, raltegravir, adverse events, dolutegravir
Abstract

Objectives The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation. Methods A population-based, prospective, multicentre cohort study was carried out. Treatment-naive subjects starting therapy with a regimen containing integrase inhibitors, or those switching to such a regimen, with plasma HIV-1 RNA < 50 HIV-1 RNA copies/mL in 14 hospitals in Catalonia or the Balearic Islands (Spain) were included in the study. Every discontinuation because of adverse events (AEs) was double-checked directly with treating physicians. Multivariable Cox models identified factors correlated with discontinuation. Results A total of 4165 subjects (37% treatment-naive) started regimens containing dolutegravir (n = 1650; 91% with abacavir), raltegravir (n = 930) or elvitegravir/cobicistat (n = 1585). There were no significant differences among regimens in the rate of discontinuation because of any AE. Rates of discontinuation because of NPAEs were low but higher for dolutegravir/abacavir/lamivudine [2.1%; 2.9 (95% confidence interval (CI) 2.0, 4.2) discontinuations/100 patients/year] versus elvitegravir/cobicistat (0.5%; 0.8 (95% CI 0.3, 1.5) discontinuations/100 patients/year], with significant differences among centres for dolutegravir/abacavir/lamivudine and NPAEs (P = 0.003). We identified an association of female gender and lower CD4 count with increased risk of discontinuation because of any AE [Incidence ratio (IR) 2.3 (95% CI 1.4, 4.0) and 1.8 (95% CI 1.1, 2.8), respectively]. Female gender, age > 60 years and abacavir use were not associated with NPAE discontinuations. NPAEs were commonly grade 1-2, and had been present before and improved after drug withdrawal. Conclusions In this large prospective cohort study, patients receiving dolutegravir, raltegravir or elvitegravir/cobicistat did not show significant differences in the rate of discontinuation because of any toxicity. The rate of discontinuations because of NPAEs was low, but was significantly higher for dolutegravir than for elvitegravir/cobicistat, with significant differences among centres, suggesting that greater predisposition to believe that a given adverse event is caused by a given drug of some treating physicians might play a role in the discordance seen between cohorts.

Published
2019

9. Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004-2016

Author

Conway, AS, Esteve, A, Fernandez-Quevedo, M, Casabona, J, Miro, JM, Riera, AB, Montoliu, A, Reyes, J, Muntada, E, Bruguera, A, Podzamczer, D, Domingo, P, Llibre, JM, Riera, S, Navarro, G, Cortes, C, Falco, V, Gatell, JM, Manzardo, C, Clotet, B, Ferrer, E, Segura, F, Force, L, Vilaro, J, Masabeu, A, Leon, E, Cifuentes, C, Homar, F, Dalmau, D, Jaen, A, Mateo, MG, Gutierrez, MD, Loureiro, E, Curran, A, Puig, T, Agusti, C, Vidal, F, Peraire, J, Orti, A, Almuedo, A, De Lazzari, E, Giralt, D, Gargoulas, F, Rubia, JC, Vila, J, Ambrosioni, J, Zamora, L, Blanco, JL, Garcia-Alcaide, F, Martinez, E, Mallolas, J, Sirera, G, Romeu, J, Jou, A, Negredo, E, Saumoy, M, Imaz, A, Bolao, F, Cabellos, C, Pena, C, DiYacovo, S, Van Den Eynde, E, Sala, M, Cervantes, M, Amengual, MJ, Navarro, M, Segura, V, Barrufet, P, Payeras, T, Gurgui, M, Utrillo, L, Meyer, S, and Hernandez, J

Subjects
Migrant health, Spain, Cohort, HIV, HIV inequalities, Late presentation with HIV
Abstract

This study using the Catalan PISCIS cohort explores risk factors of migrants' late presentation and the impact of late presentation on their health outcomes. We analyse 9590 new HIV diagnoses enrolled in the cohort between 2004 and 2016. Univariate and multivariate logistic regression models are used to identify risk factors associated with late presentation among migrants, giving crude and adjusted odds ratios and their 95% confidence intervals. Cox regression models are estimated to identify risk factors associated with AIDS/death, and crude and adjusted hazard ratios and 95% confidence intervals are reported. Late presentation is higher in migrants than non-migrants. Among migrants, region of origin is associated with late presentation and AIDS/death during follow-up. The results highlight persisting inequalities in HIV diagnosis and care among migrants in Catalonia. Targeted interventions addressed to specific subgroups in the migrant population are needed.

Published
2019

12. Intrathoracic fat in HIV-infected patients

Author

Blanco, J L, Biglia, A, Martinez, E, Sánchez, M, de Lazzari, E, Leon, A, Milinkovic, A, Larrousse, M, Lonca, M, Laguno, M, Mallolas, J, and Gatell, J M

Published
2006

14. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Author

Blanco, JL, Rojas, J, Paredes, R, Negredo, E, Mallolas, J, Casadella, M, Clotet, B, Gatell, JM, de Lazzari, E, and Martinez, E

Abstract

Background: No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these options would have similar efficacy to triple ART. Methods: We used an open-label non-inferiority randomized controlled trial comprising two phases: phase A was established to test that experimental arms did not have an unacceptable (>= 5%) failure rate; phase B was intended to include the full number of patients followed for 48 weeks. Treated HIV-1-infected adults with viral load,50 copies/mL for >= 12months, no prior viral failure or resistance mutations to study drugs, nadir CD4.200 cells/mm(3), and hepatitis B virus surface antigen negative were randomized 1: 1: 1 to maintain triple therapy (control arm), or to switch to dolutegravir/lamivudine, or to dolutegravir monotherapy stratifying by anchor drug. Premature discontinuation was considered if viral failure or therapy interruption due to adverse events, concurrent illness, protocol deviation or patient's wish occurred. Blips were registered. Planned phase A results at 24 weeks are reported here. The study is registered at EudraCT: 201500027435. Results: Ninety-one (control, n = 31; dual therapy, n = 29; monotherapy, n = 31) patients were randomized. Three patients (none previously exposed to integrase inhibitors) prematurely discontinued treatment due to viral failure: dolutegravir/lamivudine (n = 1), no resistance mutations (subject A); dolutegravir (n = 2), N155H, S147G and Q148R resistance mutations (subject B), and E138K, G140S and N155H resistance mutations (subject C). There were no discontinuations for other reasons. One patient (dolutegravir/lamivudine) experienced a blip in viral load. The Data Safety Monitoring Board recommended stopping the dolutegravir monotherapy arm. Conclusions: In contrast to dolutegravir/lamivudine, a higher than expected risk of viral failure with development of cross-resistance integrase mutations occurred with dolutegravir maintenance monotherapy.

Published
2018

15. Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis

Author

Athan, E., Harris, O., Korman, T. M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C. Q., Garcia, P., Jones, S. B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M. P., Pafundi, P. C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M. F., Baban, T., Kanafani, Z. A., Kanj, S. S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D. R., Premru, M. M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Maria, C., Garcia-Gonzalez, J., Gatell, J. M., Marco, F., Miro, J. M., Moreno, A., Ortiz, J., Ninot, S., Pare, J. C., Pericas, J. M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J. M., Vidal, B., Vila, J., Bouza, E., Rodriguez-Creixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G. R., Reller, L. B., Fowler, V. G., Chu, V. H., Messina, J. A., Park, L., Sharma-Kuinkel, B. K., Carugati, M., Munoz, P., Baloch, K., Dixon, C. C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L. P., Redick, T., Stafford, J., Anstrom, K., Bayer, A. S., Cabell, C. H., Karchmer, A. W., Sexton, D. J., Wang, A., Chu, V., Durack, D. T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Duke University Medical Center, University of Barcelona, Medical University of South Carolina [Charleston] (MUSC), American University of Beirut [Beyrouth] (AUB), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Université de Tsukuba = University of Tsukuba, Pericàs, J M, Messina, J A, Garcia-de-la-Mària, C, Park, L, Sharma-Kuinkel, B K, Marco, F, Wray, D, Kanafani, Z A, Carugati, M, Durante Mangoni, E, Tattevin, P, Chu, V H, Moreno, A, Fowler, V G, Miró, J M, De Feo, Marisa, Athan, E11, Harris, O11, Korman, Tm12, Kotsanas, D13, Jones, P14, Reinbott, P14, Ryan, S14, Fortes, Cq15, Garcia, P16, Jones, Sb16, Barsic, B17, Bukovski, S17, Selton-Suty, C18, Aissa, N18, Doco-Lecompte, T18, Delahaye, F19, Vandenesch, F19, Tattevin, P20, Hoen, B21, Plesiat, P21, Giamarellou, H22, Giannitsioti, E22, Tarpatzi, E22, Durante-Mangoni, E23, Iossa, D23, Orlando, S23, Ursi, Mp23, Pafundi, Pc23, D' Amico, F23, Bernardo, M23, Cuccurullo, S23, Dialetto, G23, Covino, Fe23, Manduca, S23, DELLA CORTE, Alessandro, De Feo, M23, Tripodi, Mf24, Baban, T25, Kanafani, Za25, Kanj, Ss25, Sfeir, J25, Yasmine, M25, Morris, A26, Murdoch, Dr27, Premru, Mm28, Lejko-Zupanc, T28, Almela, M29, Ambrosioni, J29, Azqueta, M29, Brunet, M29, Cervera, C29, De Lazzari, E29, Falces, C29, Fuster, D29, Garcia-de-la-Mària, C29, Garcia-Gonzalez, J29, Gatell, Jm29, Marco, F29, Miró, Jm29, Moreno, A29, Ortiz, J29, Ninot, S29, Paré, Jc29, Pericas, Jm29, Quintana, E29, Ramirez, J29, Sandoval, E29, Sitges, M29, Tolosana, Jm29, Vidal, B29, Vila, J29, Bouza, E30, Muñoz, P, Rodríguez-Créixems, M30, Ramallo, V30, Bradley, S31, Wray, D32, Steed, L32, Cantey, R32, Peterson, G33, Stancoven, A33, Woods, C34, Corey, Gr34, Reller, Lb34, Fowler VG, Jr34, Chu, Vh34, Baloch, K, Chu, Vh, Corey, Gr, Dixon, Cc, Fowler VG, Jr, Harding, T, Jones-Richmond, M, Pappas, P, Park, Lp, Redick, T, Stafford, J, Anstrom, K, Athan, E, Bayer, A, Cabell, Ch, Hoen, B, Karchmer, Aw, Miró, Jm, Murdoch, Dr, Sexton, Dj, Wang, A, Chu, V, Durack, Dt, Eykyn, S, Moreillon, P, Olaison, L, Raoult, D, Rubinstein, E, and Sexton, Dj.

Subjects
0301 basic medicine, Male, medicine.disease_cause, 0302 clinical medicine, 80 and over, Medicaments antibacterians, 030212 general & internal medicine, Endocarditi, Prospective Studies, Aged, 80 and over, Endocarditis, Bacterial, General Medicine, Middle Aged, Staphylococcal Infections, 3. Good health, Anti-Bacterial Agents, Fenotip, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Treatment Outcome, Phenotype, Staphylococcus aureus, Infective endocarditis, Staphylococcus aureu, Vancomycin, Genotype, Vancomycin MIC, Adult, Aged, Endocarditis, Bacterial, Female, Humans, Microbial Sensitivity Tests, Molecular Typing, Multiplex Polymerase Chain Reaction, Survival Analysis, Virulence Factors, beta-Lactams, medicine.drug, Microbiology (medical), 030106 microbiology, Biology, Staphylococcal infections, Article, Microbiology, 03 medical and health sciences, Minimum inhibitory concentration, medicine, Etest, Endocarditis Staphylococcus aureus, biochemical phenomena, metabolism, and nutrition, medicine.disease, Antibacterial agents, Methicillin Susceptible Staphylococcus Aureus
Abstract

Objectives: Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >= 1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (> 1.5mg/L) phenotype.Methods: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>= 1.5 mg/L) or low (

Published
2017

17. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal beta-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.

Author

Ambrosioni J., Covino F.E., Manduca S., Della Corte A., De Feo M., Tripodi M.F., Baban T., Kanj S.S., Sfeir J., Yasmine M., Morris A., Murdoch D.R., Premru M.M., Lejko-Zupanc T., Almela M., Azqueta M., Brunet M., Cervera C., De Lazzari E., Falces C., Fuster D., Garcia-Gonzalez J., Gatell J.M., Ortiz J., Ninot S., Pare J.C., Quintana E., Ramirez J., Sandoval E., Sitges M., Tolosana J.M., Vidal B., Vila J., Bouza E., Rodriguez-Creixems M., Ramallo V., Bradley S., Steed L., Cantey R., Peterson G., Stancoven A., Woods C., Reller L.B., Pericas J.M., Garcia-de-la-Maria C., Moreno A., Marco F., Sharma-Kuinkel B.K., Carugati M., Messina J.A., Park L., Wray D., Kanafani Z.A., Tattevin P., Munoz P., Baloch K., Dixon C.C., Harding T., Jones-Richmond M., Pappas P., Park L.P., Redick T., Stafford J., Anstrom K., Athan E., Chu V.H., Karchmer A.W., Wang A., Bayer A.S., Cabell C.H., Chu V., Corey G.R., Durack D.T., Eykyn S., Fowler V.G., Hoen B., Miro J.M., Sexton D.J., Moreillon P., Olaison L., Raoult D., Rubinstein E., Harris O., Korman T.M., Kotsanas D., Jones P., Reinbott P., Ryan S., Fortes C.Q., Garcia P., Jones S.B., Barsic B., Bukovski S., Selton-Suty C., Aissa N., Doco-Lecompte T., Delahaye F., Vandenesch F., Plesiat P., Giamarellou H., Giannitsioti E., Tarpatzi E., Durante-Mangoni E., Iossa D., Orlando S., Ursi M.P., Pafundi P.C., D' Amico F., Bernardo M., Cuccurullo S., Dialetto G., Ambrosioni J., Covino F.E., Manduca S., Della Corte A., De Feo M., Tripodi M.F., Baban T., Kanj S.S., Sfeir J., Yasmine M., Morris A., Murdoch D.R., Premru M.M., Lejko-Zupanc T., Almela M., Azqueta M., Brunet M., Cervera C., De Lazzari E., Falces C., Fuster D., Garcia-Gonzalez J., Gatell J.M., Ortiz J., Ninot S., Pare J.C., Quintana E., Ramirez J., Sandoval E., Sitges M., Tolosana J.M., Vidal B., Vila J., Bouza E., Rodriguez-Creixems M., Ramallo V., Bradley S., Steed L., Cantey R., Peterson G., Stancoven A., Woods C., Reller L.B., Pericas J.M., Garcia-de-la-Maria C., Moreno A., Marco F., Sharma-Kuinkel B.K., Carugati M., Messina J.A., Park L., Wray D., Kanafani Z.A., Tattevin P., Munoz P., Baloch K., Dixon C.C., Harding T., Jones-Richmond M., Pappas P., Park L.P., Redick T., Stafford J., Anstrom K., Athan E., Chu V.H., Karchmer A.W., Wang A., Bayer A.S., Cabell C.H., Chu V., Corey G.R., Durack D.T., Eykyn S., Fowler V.G., Hoen B., Miro J.M., Sexton D.J., Moreillon P., Olaison L., Raoult D., Rubinstein E., Harris O., Korman T.M., Kotsanas D., Jones P., Reinbott P., Ryan S., Fortes C.Q., Garcia P., Jones S.B., Barsic B., Bukovski S., Selton-Suty C., Aissa N., Doco-Lecompte T., Delahaye F., Vandenesch F., Plesiat P., Giamarellou H., Giannitsioti E., Tarpatzi E., Durante-Mangoni E., Iossa D., Orlando S., Ursi M.P., Pafundi P.C., D' Amico F., Bernardo M., Cuccurullo S., and Dialetto G.

Abstract

Objectives Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >=1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (>=1.5 mg/L) phenotype. Methods All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>=1.5 mg/L) or low (<1.5 mg/L). Isolates underwent spa typing to infer clonal complexes and multiplex PCR for identifying virulence genes. Univariate analysis was performed to evaluate the association between in-hospital and 1-year mortality, and vancomycin MIC phenotype. Results Sixty-two cases met the inclusion criteria. Vancomycin MIC was low in 28 cases (45%) and high in 34 cases (55%). No significant differences in patient demographic data or characteristics of infection were observed between patients with infective endocarditis due to high and low vancomycin MIC isolates. Isolates with high and low vancomycin MIC had similar distributions of virulence genes and clonal lineages. In-hospital and 1-year mortality did not differ significantly between the two groups (32% (9/28) vs. 27% (9/34), p 0.780; and 43% (12/28) vs. 29% (10/34), p 0.298, for low and high vancomycin MIC respectively). Conclusions In this international cohort of patients with left-sided MSSA endocarditis treated with antistaphylococcal beta-lactams, vancomycin MIC phenotype was not associated with patient demographics, clinical outcome or virulence gene repertoire.Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases

Published
2017

18. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

Author

Aga¼ero, F., Rimola, A., Stock, P., Grossi, P., Rockstroh, J. K., Agarwal, K., Garzoni, C., Barcan, L. A., Maltez, F., Manzardo, C., Mari, M., Ragni, M. V., Anadol, E., Di Benedetto, F., Nishida, S., Gastaca, M., Mira, J. M., Pedreira, J. D., Castro, M. A., Lapez, S., Sua¡rez, F., Vazquez, P., Blanch, J., Brunet, M., Cervera, C., de Lazzari, E., Fondevila, C., Forner, A., Fuster, J., Freixa, N., GarcA­a-Valdecasas, J. C., Gil, A., Gatell, J. M., Laguno, M., Marta­nez, M., Mallolas, J., Monras, M., Moreno, A., Murillas, J., Paredes, D., Pacopyrightrez, I., Torres, F., Tural, C., Tuset, M., Antela, A., Fernandez, J., Losada, E., Varo, E., Lozano, R., Araiz, J. J., Barrao, E., Letona, S., Luque, P., Navarro, A., Sanjoaqua­n, I., Serrano, T., Tejero, E., Salcedo, M., BaA+/-ares, R., Calleja, J., Berenguer, J., Cosa­n, J., Gutiacopyrightrrez, I., Lapez, J. C., Miralles, P., Rama­rez, M., Rincan, D., Sanchez, M., Jimacopyrightnez, M., de la Cruz, J., Ferna¡ndez, J. L., Lozano, J. M., Santoyo, J., Rodrigo, J. M., Sua¡rez, M. A., Rodra­guez, M., Alonso, M. P., Asensi, V., Gonza¡lez, M. L., GonzA¡lez-Pinto, I., Rafecas, A., Carratala¡, J., Fabregat, J., Ferna¡ndez, N., Xiol, X., Montejo, M., Bustamante, J., Ferna¡ndez, J. R., Montejo, E., Ortiz de Urbina, J., Ruiz, P., Sua¡rez, M. J., Testillano, M., Valdivieso, A., Ventoso, A., Abradelo, M., Costa, J. R., Fundora, Y., Jimacopyrightnez, S., Meneu, J. C., Moreno, E., Moreno, V., Olivares, S. P., Pacopyrightrez, B., Pulido, F., Rubio, R., Blanes, M., Aguilera, V., Berenguer, M., Lapez, J., Lapez, R., Prieto, M., FariA+/-as, M. C., Arnaiz, A., Casafont, F., Echevarria, S., Fa¡brega, E., Garca­a, J. D., Gamez, M., Gutiacopyrightrrez, J. M., Peralta, F. G., Teira, R., Moreno, S., Barcena, R., Del Campo, S., Fortaºn, J., Moreno, A. M., Torre-Cisneros, J., Barrera, P., Camacho, A., Cantisa¡n, S., Castan, J. J., de la Mata, M., Lara, M. R., Natera, C., Rivero, A., Vidal, E., Castells, L. I., Charco, R., Esteban, J. I., Gavalda¡, J., Len, O., Pahissa, A., Ribera, E., Vargas, V., Pons, J. A., Cordero, E., Bernal, C., Cisneros, J. M., Gamez, M. A., Pascasio, J. M., Rodra­guez, M. J., Sayazo, M., Sousa, J. M., Sua¡rez, G., Gonza¡lez, J., Aznar, E., Barquilla, E., Esteban, H., Krahe, L., Moyano, B., de la Rosa, G., Mahillo, B., Roland, M., Ascher, N., Roberts, J., Freise, C., Terrault, N., Carlson, L., Beatty, G., Chin-Hong, P., Dove, L., Emond, J., Lobritto, S., Neu, N., Yin, M., Kumar, A., Ringe, B., Jacobson, J., Sass, D., Diego, J., Tzakis, A., Roth, D., Schiff, E., Burke, G., Jayaweera, D., Olthoff, K., Blumberg, E., Bloom, R., Reddy, R., Ragni, M., Shapiro, R., De Vera, M. E., Shakil, O., Simon, D., Cohen, S. M., Dodson, S. F., Jensik, S., Saltzberg, S., Stosor, T., Green, R., Baker, T., Gallon, L., Scarsi, K., Hanto, D., Wong, M., Curry, M., Johnson, S., Pavlakis, M., Barin, B., Risaliti, A., Ancarani, F., Pinna, A. D., Morelli, C., Guaraldi, G., Tarantino, G., Baccarani, U., Tavio, M., Nanni Costa, A., Beckebaum, S., Radecke, K., Bickel, M., Sterneck, M., Zoufaly, A., Ganten, T., Stoll, M., Salzberger, B., Berg, C., Kittner, J., O'Grady, J., Joshi, D., Heaton, N., Smud, A., Genoud, N., Cahn, F., Valledor, A., Gadano, A., Barcan, L., Cusini, A., Rauch, A., Furrer, H., Ma¼ller, N. J., Khanna, N., van Delden, C., Oriol, M., Manata, M. J., Correia, F., Machado, J., Morbey, A., Glaria, H., Veloso, J., Perdigoto, R., Pereira, P., Martins, A., and Barroso, E.

Subjects
Male, medicine.medical_treatment, HCC INF, HIV Infections, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Gastroenterology, Cohort Studies, 0302 clinical medicine, Postoperative Complications, Risk Factors, Adult, Coinfection, Female, Follow-Up Studies, Graft Survival, HIV-1, Hepatitis B, Hepatitis B virus, Hepatitis C, Humans, International Agencies, Middle Aged, Prognosis, Reoperation, Survival Rate, Liver Transplantation, Immunology and Allergy, Transplantation, Pharmacology (medical), virus diseases, 3. Good health, 030211 gastroenterology & hepatology, medicine.medical_specialty, Hepatitis C virus, 03 medical and health sciences, Internal medicine, medicine, Survival rate, business.industry, medicine.disease, digestive system diseases, Surgery, business
Abstract

Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents. info:eu-repo/semantics/publishedVersion

Published
2016

19. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis

Author

Pericàs, J.M., primary, Messina, J.A., additional, Garcia-de-la-Mària, C., additional, Park, L., additional, Sharma-Kuinkel, B.K., additional, Marco, F., additional, Wray, D., additional, Kanafani, Z.A., additional, Carugati, M., additional, Durante-Mangoni, E., additional, Tattevin, P., additional, Chu, V.H., additional, Moreno, A., additional, Fowler, V.G., additional, Miró, J.M., additional, Athan, E., additional, Harris, O., additional, Korman, T.M., additional, Kotsanas, D., additional, Jones, P., additional, Reinbott, P., additional, Ryan, S., additional, Fortes, C.Q., additional, Garcia, P., additional, Jones, S.B., additional, Barsic, B., additional, Bukovski, S., additional, Selton-Suty, C., additional, Aissa, N., additional, Doco-Lecompte, T., additional, Delahaye, F., additional, Vandenesch, F., additional, Hoen, B., additional, Plesiat, P., additional, Giamarellou, H., additional, Giannitsioti, E., additional, Tarpatzi, E., additional, Iossa, D., additional, Orlando, S., additional, Ursi, M.P., additional, Pafundi, P.C., additional, D' Amico, F., additional, Bernardo, M., additional, Cuccurullo, S., additional, Dialetto, G., additional, Covino, F.E., additional, Manduca, S., additional, Della Corte, A., additional, De Feo, M., additional, Tripodi, M.F., additional, Baban, T., additional, Kanj, S.S., additional, Sfeir, J., additional, Yasmine, M., additional, Morris, A., additional, Murdoch, D.R., additional, Premru, M.M., additional, Lejko-Zupanc, T., additional, Almela, M., additional, Ambrosioni, J., additional, Azqueta, M., additional, Brunet, M., additional, Cervera, C., additional, De Lazzari, E., additional, Falces, C., additional, Fuster, D., additional, Garcia-Gonzalez, J., additional, Gatell, J.M., additional, Ortiz, J., additional, Ninot, S., additional, Paré, J.C., additional, Pericas, J.M., additional, Quintana, E., additional, Ramirez, J., additional, Sandoval, E., additional, Sitges, M., additional, Tolosana, J.M., additional, Vidal, B., additional, Vila, J., additional, Bouza, E., additional, Muñoz, P., additional, Rodríguez-Créixems, M., additional, Ramallo, V., additional, Bradley, S., additional, Steed, L., additional, Cantey, R., additional, Peterson, G., additional, Stancoven, A., additional, Woods, C., additional, Corey, G.R., additional, Reller, L.B., additional, Baloch, K., additional, Dixon, C.C., additional, Harding, T., additional, Jones-Richmond, M., additional, Pappas, P., additional, Park, L.P., additional, Redick, T., additional, Stafford, J., additional, Anstrom, K., additional, Bayer, A.S., additional, Cabell, C.H., additional, Karchmer, A.W., additional, Sexton, D.J., additional, Wang, A., additional, Chu, V., additional, Durack, D.T., additional, Eykyn, S., additional, Moreillon, P., additional, Olaison, L., additional, Raoult, D., additional, and Rubinstein, E., additional

Published
2017
Full Text
View/download PDF

20. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Author

Laguno, M., primary, Von Wichmann, M.A., additional, Van den Eynde, E., additional, Navarro, J., additional, Cifuentes, C., additional, Murillas, J., additional, Veloso, S., additional, Martínez-Rebollar, M., additional, Guardiola, J.M., additional, Jou, A., additional, Gómez-Sirvent, J.L., additional, Cervantes, M., additional, Pineda, J.A., additional, López-Calvo, S., additional, Carrero, A., additional, Montes, M.L., additional, Deig, E., additional, Tapiz, A., additional, Ruiz-Mesa, J.D., additional, Cruceta, A., additional, de Lazzari, E., additional, and Mallolas, J., additional

Published
2016
Full Text
View/download PDF

21. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition

Author

Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr, among ICE PCS Investigators, UTILI, Riccardo, Humbert, Murielle, Benito, N, Miró, Jm, de Lazzari, E, Cabell, Ch, del Río, A, Altclas, J, Commerford, P, Delahaye, F, Dragulescu, S, Giamarellou, H, Habib, G, Kamarulzaman, A, Kumar, A, Nacinovich, Fm, Suter, F, Tribouilloy, C, Venugopal, K, Moreno, A, Fowler VG, Jr, among ICE PCS, Investigator, and Utili, Riccardo

Subjects
Adult, Male, medicine.medical_specialty, Article, Ambulatory care, Renal Dialysis, Risk Factors, Health care, Epidemiology, Internal Medicine, medicine, Ambulatory Care, Endocarditis, Humans, Prospective Studies, Intensive care medicine, Aged, Ultrasonography, Native Valve Endocarditis, Cross Infection, business.industry, Public health, nosocomial, General Medicine, Endocarditis, Bacterial, Middle Aged, medicine.disease, Cardiac surgery, Community-Acquired Infections, Treatment Outcome, Endocarditis, nosocomial, S.aureus, S.aureus, Bacteremia, endocarditis, health-care associated infections, Female, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, business
Abstract

BACKGROUND: The clinical profile and outcome of nosocomial and non-nosocomial health care-associated native valve endocarditis are not well defined. OBJECTIVE: To compare the characteristics and outcomes of community-associated and nosocomial and non-nosocomial health care-associated native valve endocarditis. DESIGN: Prospective cohort study. SETTING: 61 hospitals in 28 countries. PATIENTS: Patients with definite native valve endocarditis and no history of injection drug use who were enrolled in the ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) from June 2000 to August 2005. MEASUREMENTS: Clinical and echocardiographic findings, microbiology, complications, and mortality. RESULTS: Health care-associated native valve endocarditis was present in 557 (34%) of 1622 patients (303 with nosocomial infection [54%] and 254 with non-nosocomial infection [46%]). Staphylococcus aureus was the most common cause of health care-associated infection (nosocomial, 47%; non-nosocomial, 42%; P = 0.30); a high proportion of patients had methicillin-resistant S. aureus (nosocomial, 57%; non-nosocomial, 41%; P = 0.014). Fewer patients with health care-associated native valve endocarditis had cardiac surgery (41% vs. 51% of community-associated cases; P < 0.001), but more of the former patients died (25% vs. 13%; P < 0.001). Multivariable analysis confirmed greater mortality associated with health care-associated native valve endocarditis (incidence risk ratio, 1.28 [95% CI, 1.02 to 1.59]). LIMITATIONS: Patients were treated at hospitals with cardiac surgery programs. The results may not be generalizable to patients receiving care in other types of facilities or to those with prosthetic valves or past injection drug use. CONCLUSION: More than one third of cases of native valve endocarditis in non-injection drug users involve contact with health care, and non-nosocomial infection is common, especially in the United States. Clinicians should recognize that outpatients with extensive out-of-hospital health care contacts who develop endocarditis have clinical characteristics and outcomes similar to those of patients with nosocomial infection. PRIMARY FUNDING SOURCE: None.

Published
2009

22. I TEATRI PERDUTI DI PADOVA

Author

CATTIODORO, Silvia, AUTIZI, MB, LITARDI, A, MACCHIETTO, M, BOBISUT, D, CONTE, R, SCARPA, F, POSSAMAI VITA, A, BEDIN, N, BOSCARDIN, L, SCARSO, M, DE LAZZARI, E, BRUNETTA MENATO, M, CAMPAGNARO, L, PATRONE, P, GASTALDI, E, AVESANI, R, MATINO, U, GIORATO, S, ZANON, T, REBESCHINI, C, BERGAMIN, N, VEDOVATO, M, MONTI, G, TOSATO, R, MURATORI, G, GUMIERO SALOMONI, L, BELLINATI, A., MIRELLA CISOTTO NALON, CATTIODORO, S, AUTIZI, MB, LITARDI, A, MACCHIETTO, M, BOBISUT, D, CONTE, R, SCARPA, F, POSSAMAI VITA, A, BEDIN, N, BOSCARDIN, L, SCARSO, M, DE LAZZARI, E, BRUNETTA MENATO, M, CAMPAGNARO, L, PATRONE, P, GASTALDI, E, AVESANI, R, MATINO, U, GIORATO, S, ZANON, T, REBESCHINI, C, BERGAMIN, N, VEDOVATO, M, MONTI, G, TOSATO, R, MURATORI, G, GUMIERO SALOMONI, L, and BELLINATI, A

Subjects
TEATRO, PADOVA, SPETTACOLO
Published
2004

23. TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

Author

Efsen, A. M. W., Panteleev, A. M., Grint, D., Podlekareva, D. N., Vassilenko, A., Rakhmanova, A., Zeltina, I., Losso, M. H., Miller, R. F., Girardi, E., Cayla, J., Post, F. A., Miro, J. M., Bruyand, M., Furrer, H., Obel, N., Lundgren, J. D., Mocroft, A., Kirk, O., Toibaro, J. J., Warley, E., Tamayo, N., Cristina Ortiz, M., Scapelatto, P., Bottaro, E., Murano, F., Miachans, M., Contarelli, J., Massera, L., Corral, J., Hualde, M., Miglioranza, C., Corti, M., Metta, H., Casiro, A., Cuini, R., Laplume, H., David, D., Marson, C., Lupo, S., Trape, L., Garcia Messina, O., Gear, O., Bruguera, J. M., Karpov, I., Skrahina, E., Skrahin, A., Zhavoronok, S., Mitsura, V., Ruzanov, D., Bondarenko, V., Suetnov, O., Paduto, D., Gerstoft, J., Kronborg, G., Pedersen, C., Larsen, C. S., Pedersen, G., Laursen, A. L., Nielsen, L., Jensen, J., Dabis, F., Chene, G., Lawson-Ayayi, S., Thiebaut, R., Wittkop, L., Morlat, P., Bonnet, F., Bernard, N., Hessamfar, M., Lacoste, D., Vandenhende, M. A., Dupon, M., Dauchy, F. A., Dutronc, H., Longy-Boursier, M., Mercie, P., Duffau, P., Roger Schmeltz, J., Malvy, D., Pistone, T., Receveur, M. C., Neau, D., Cazanave, C., Ochoa, A., Vareil, M. O., Pellegrin, J. L., Viallard, J. F., Greib, C., Lazaro, E., Fleury, H., Lafon, M. E., Reigadas, S., Trimoulet, P., Breilh, D., Molimard, M., Bouchet, S., Titier, K., Moreau, J. F., Pellegrin, I., Haramburu, F., Arcachon, G., Dupont, A., Gerard, Y., Caunegre, L., Andre, K., Bonnal, F., Farbos, S., Gemain, M. C., Ceccaldi, J., Tchamgoue, S., De Witte, S., Courtault, K., Monlun, E., Gaborieau, V., Lataste, P., Meraud, J. P., Chossat, I., Carvalho, A. C., Basche, R., Hamad, I. E., Ricci, B. A., Maggiolo, F., Ravasio, V., Mussini, C., Prati, F., Castelletti, S., Ammassari, A., Antinori, A., Bellagamba, R., Busi Rizzi, E., Cicalini, S., Corpolongo, A., Capaldo, A., Di Caro, A., Goletti, D., Grisetti, S., Gualano, G., Lauria, F. N., Parracino, L., Palmieri, F., Petrosillo, N., Pinetti, C., Sampaolesi, A., Moroni, M., Angarano, G., Armignacco, O., d'Arminio Monforte, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Guzzinati, Ippolito, Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Lo Caputo, S., Puoti, M., Andreoni, M., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Cicconi, P., Fanti, I., Formenti, T., Galli, L., Lorenzini, P., Giacometti, A., Costantini, A., Carrisa, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, G., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Puzzolante, C., Abrescia, N., Chirianni, A., Guida, M. G., Gargiulo, M., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Cattelan, A., Mura, M. S., Caramello, P., Orofino, G. C., Sciandra, M., Pellizzer, G., Manfrin, V., Riekstina, V., Aldins, P., Duiculescu, D., Malashenkov, E., Kozlov, A., Buzunova, S., Garcia-Goez, J. F., Moreno Camacho, A., Martinez, J. A., Gonzalez, J., Garcia-Alcaide, F., de Lazzari, E., Gatell, J. M., Sanchez, P., Lopezcolomes, J. L., Martinez-Lacasa, X., Falco, V., Imaz, A., Ocana, I., Vidal, R., Sambeat, M. A., Moreno-Martinez, A., Orcau, A., Weber, R., Battegay, M., Hirschel, B., Cavassini, M., Bernasconi, E., Schmid, P., Rickenbach, M., Campbell, L., Arenas-Pinto, A., Chentsova, N., Kjaer, J., Efsen, Anne Marie W., Panteleev, Alexander M., Grint, Daniel, Podlekareva, Daria N., Vassilenko, Anna, Rakhmanova, Aza, Zeltina, Indra, Losso, Marcelo H., Miller, Robert F., Girardi, Enrico, Caylã¡, Joan, Post, Frank A., Miro, Jose M., Bruyand, Mathia, Furrer, Hansjakob, Obel, Niel, Lundgren, Jens D., Mocroft, Amanda, Kirk, Ole, Hiv/tb Study, Group, Castagna, Antonella, Efsen, A, Panteleev, A, Grint, D, Podlekareva, D, Vassilenko, A, Rakhmanova, A, Zeltina, I, Losso, M, Miller, R, Girardi, E, Caylá, J, Post, F, Miro, J, Bruyand, M, Furrer, H, Obel, N, Lundgren, J, Mocroft, A, Kirk, O, and Gori, A

Subjects
Genetics and Molecular Biology (all), Male, Pediatrics, Meningeal, Immunology and Microbiology (all), lcsh:Medicine, HIV Infections, Kaplan-Meier Estimate, Rate ratio, Biochemistry, Risk Factors, Adult, Argentina, CD4 Lymphocyte Count, Europe, Female, HIV, Humans, Treatment Outcome, Tuberculosis, Meningeal, Biochemistry, Genetics and Molecular Biology (all), HIV Infection, Mortality rate, General Medicine, symbols, Meningitis, Human, Research Article, medicine.medical_specialty, Tuberculosis, Settore MED/17 - Malattie Infettive, Article Subject, General Biochemistry, Genetics and Molecular Biology, Tuberculous meningitis, NO, symbols.namesake, Pharmacotherapy, medicine, Poisson regression, General Immunology and Microbiology, business.industry, Public health, Risk Factor, lcsh:R, medicine.disease, Immunology, business
Abstract

Objectives.The study aimed at describing characteristics and outcome of tuberculous meningitis (TBM) in HIV-positive patients and comparing these parameters with those of extrapulmonary TB (TBEP) and pulmonary TB (TBP).Methods.Kaplan-Meier estimation and Poisson regression models were used to assess the mortality following TB diagnosis and to evaluate potential prognostic factors for the 3 groups of TB patients separately.Results.A total of 100 patients with TBM, 601 with TBEP, and 371 TBP were included. Patients with TBM had lower CD4 cell counts and only 17.0% received antiretroviral therapy (ART) at TB diagnosis. The cumulative probability of death at 12 months following TB was 51.2% for TBM (95% CI 41.4–61.6%), 12.3% for TBP (8.9–15.7%), and 19.4% for TBEP (16.1–22.6) (P<0.0001; log-rank test). For TBM, factors associated with a poorer prognosis were not being on ART (adjusted incidence rate ratio (aIRR) 4.00 (1.72–9.09), a prior AIDS diagnosis (aIRR=4.82(2.61–8.92)), and receiving care in Eastern Europe (aIRR=5.41(2.58–11.34))).Conclusions.TBM among HIV-positive patients was associated with a high mortality rate, especially for patients from Eastern Europe and patients with advanced HIV-infection, which urgently calls for public health interventions to improve both TB and HIV aspects of patient management.

Published
2013
Full Text
View/download PDF

24. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

Author

Podlekareva, Dn, Mocroft, A, Post, Fa, Riekstina, V, Miro, Jm, Furrer, H, Bruyand, M, Panteleev, Am, Rakhmanova, Ag, Girardi, E, Losso, Mh, Toibaro, Jj, Caylá, J, Miller, Rf, Obel, N, Skrahina, A, Chentsova, N, Lundgren, Jd, Kirk, O, Collaborators: Losso MH, HIV/TB Study Writing G. r. o. u. p., Warley, E, Tamayo, N, Cristina Ortiz, M, Santojanni, F, Scapelatto, P, Bottaro, E, Murano, F, Miachans, M, Contarelli, J, Massera, L, Corral, J, Hualde, M, Miglioranza, C, Corti, M, Metta, H, Casiró, A, Cuini, R, Laplume, H, David, D, Marson, C, Lupo, S, Trape, L, Garcia Messina, O, Gear, O, Ramos Mejía JM, Bruguera, Jm, Karpov, I, Vasilenko, A, Skrahina, E, Skrahin, A, Zhavoronok, S, Mitsura, V, Ruzanov, D, Bondarenko, V, Suetnov, O, Paduto, D, Gerstoft, J, Kronborg, G, Pedersen, C, Larsen, Cs, Pedersen, G, Laursen, Al, Nielsen, L, Jensen, J, Dabis, F, Chêne, G, Lawson Ayayi, S, Thiébaut, R, Winnock, M, Bernard, N, Dupon, M, Lacoste, D, Malvy, D, Mercié, P, Morlat, P, Neau, D, Pellegrin, Jl, Ragnaud, Jm, Moreau, Jf, Blanco, P, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Blaizeau, Mj, Decoin, M, Delveaux, S, Dutoit, D, Geffard, S, Hannapier, C, Houinou, L, Labarrère, S, Lavignolle Aurillac, V, Palmer, G, Touchard, D, Bonarek, M, Bonnet, F, Lacombe, K, Gellie, P, Paccalin, F, Pertusa, Mc, Dutronc, H, Dauchy, F, Lafarie, S, Longy Boursier, M, Pistonne, T, Receveur, Mc, Thibaut, P, Cazorla, C, Chambon, D, De La Taille, C, Galpérine, T, Ochoa, A, Viallard, Jf, Caubet, O, Nouts, C, Couzigou, P, Castera, L, Loste, P, Caunègre, L, Bonnal, F, Farbos, S, Gemain, Mc, Ceccaldi, J, Tchamgoue, S, Witte, Sd, Carvalho, Ac, Basché, R, Hamad, Ie, Ricci, Ba, Maggiolo, F, Ravasio, V, Mussini, C, Prati, F, Castelletti, S, Spallanzani, L, Antinori, A, Antonucci, G, Bibbolino, C, Bove, G, Busi Rizzi, E, Cicalini, S, Conte, A, Cuzzi, G, De Mori, P, Festa, A, Goletti, D, Grisetti, S, Gualano, G, Lauria, Fn, Maddaluno, R, Migliorisi Ramazzini, P, Narciso, P, Parracino, L, Palmieri, F, Petrosillo, N, Pucillo, L, Puro, V, Vanacore, P, Urso, R, Moroni, M, Carosi, Giampiero, Cauda, R, Chiodo, F, d'Arminio Monforte, A, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Mazzotta, F, Panebianco, R, Pastore, G, Perno, Cf, Ammassari, A, Arici, C, Balotta, C, Bonfanti, P, Capobianchi, Mr, Castagna, A, Ceccherini Silberstein, F, Cozzi Lepri, A, De Luca, A, Gervasoni, C, Lo Caputo, S, Murri, R, Puoti, Massimo, Torti, Carlo, Fanti, I, Formenti, T, Prosperi, M, Montroni, M, Giacoemtti, A, Costantini, A, Riva, A, Tirelli, U, Martellotta, F, Ladisa, N, Suter, F, Verucchi, G, Fiorini, C, Carosi, G, Cristini, G, Torti, C, Minardi, C, Bertelli, D, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Pizzigallo, E, Dalessandro, M, Carnevale, G, Lorenzotti, S, Ghinelli, F, Sighinolfi, L, Leoncini, F, Pozzi, M, Pagano, G, Cassola, G, Viscoli, G, Alessandrini, A, Piscopo, R, Soscia, F, Tacconi, L, Orani, A, Rossotto, R, Tommasi, D, Congedo, P, Chiodera, A, Castelli, P, Rizzardini, G, Schlacht, I, Ridolfo, Al, Foschi, A, Salpietro, S, Merli, S, Melzi, S, Moioli, Mc, Cicconi, P, Esposito, R, Gori, A, Borrello, A, Abrescia, N, Chirianni, A, Izzo, Cm, De Marco, M, Viglietti, R, Manzillo, E, Ferrari, C, Pizzaferri, P, Baldelli, F, Camanni, G, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Andreoni, M, Tozzi, V, Vullo, V, Zaccarelli, M, Acinapura, R, De Longis, P, Trotta, Mp, Lichtner, M, Carletti, F, Mura, Ms, Madeddu, G, Caramello, P, Orofino, Gc, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Aldins, P, Duiculescu, D, Rakhmanova, A, Malashenkov, E, Kozlov, A, Panteleev, A, Buzunova, S, García Goez JF, Moreno Camacho, A, Martínez, Ja, González, J, García Alcaide, F, de Lazzari, E, Gatell, Jm, Sanchez, P, Lopez Colomes JL, Martínez Lacasa, X, Falcó, V, Imaz, A, Ocaña, I, Vidal, R, Sambeat, Ma, Caylà, J, Moreno Martínez, A, Orcau, A, Weber, R, Battegay, M, Hirschel, B, Cavassini, M, Bernasconi, E, Schmid, P, Rickenbach, M, Post, F, Campbell, L, Miller, R, Arenas Pinto, A, Podlekareva, D, Kjaer, J, Ellefson, M, and Toibaro, J. J.

Subjects
HIV/TB coinfection, Eastern Europe, Western Europe, Argentina
Published
2009

27. Staphylococcus lugdunensis infective endocarditis. Description of 10 cases and analysis of native valve, prosthetic valve and pacemaker lead endocarditis clinical profiles

Author

Universitat de Barcelona, Anguera Camós, Ignasi, Rio Bueno, Anna del, Miró Meda, José M., Martínez Lacasa, Javier-Tomás, Marco Reverté, Francesc, Gumá, J. R., Quaglio, G., Claramonte, X., Moreno Camacho, Ma. Asunción, Mestres Lucio, Carlos-Alberto, Mauri, E., Azqueta, Manuel, Benito Hernández, M. Natividad de, García de la Mària, Cristina, Almela, M. (Manel), Jiménez Expósito, María Jesús, Sued, Omar, De Lazzari, E., Gatell, José M., Universitat de Barcelona, Anguera Camós, Ignasi, Rio Bueno, Anna del, Miró Meda, José M., Martínez Lacasa, Javier-Tomás, Marco Reverté, Francesc, Gumá, J. R., Quaglio, G., Claramonte, X., Moreno Camacho, Ma. Asunción, Mestres Lucio, Carlos-Alberto, Mauri, E., Azqueta, Manuel, Benito Hernández, M. Natividad de, García de la Mària, Cristina, Almela, M. (Manel), Jiménez Expósito, María Jesús, Sued, Omar, De Lazzari, E., and Gatell, José M.

Abstract

bolism. Surgery was needed in 51% of cases and mortality was 42%. Prosthetic valve endocarditis (nine of 60, 13%) predominated in the aortic position and was associated with abscess formation, required surgery, and high mortality (78%). Pacemaker lead IE (seven of 69, 10%) is associated with a better prognosis when antibiotic treatment is combined with surgery. Conclusions:S lugdunensis IE is an uncommon cause of IE, involving mainly native left sided valves, and it is characterised by an aggressive clinical course. Mortality in left sided native valve IE is high but the prognosis has improved in recent years. Surgery has improved survival in left sided IE and, therefore, early surgery should always be considered. Prosthetic valve S lugdunensis IE carries an ominous prognosis.

Published
2012

28. Simplification with fixed-dose Tenofovir-Emtricitabine or Abacavir-Lamivudine in treatment experienced, virologically suppressed adults with Hiv infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal

Author

Amin, Janaki, De Lazzari, E, Emery, Sean, Martin, Allison, Martinez, E, Carr, Andrew, Gatell, J, Cooper, David A, Amin, Janaki, De Lazzari, E, Emery, Sean, Martin, Allison, Martinez, E, Carr, Andrew, Gatell, J, and Cooper, David A

Abstract

Background: There is uncertainty about the comparative safety and effi cacy of the fi xed-dose-combination tablets tenofovir 300mg+emtricitabine 200mg (TDF/FTC); and abacavir 600mg+lamivudine 300mg (ABC/3TC). Methods: We used random effects meta-analysis to compare 96 week data for ABC/3TC and TDF/FTC randomised arms from the BICOMBO (n=333) and STEAL (n=357) treatment experienced and virologically suppressed switch studies. Endpoints included: virological failure (VF, repeat plasma HIV RNA >400 copies/mL); mean change to week 96 in CD4 and metabolic parameters; proportion with serious non-AIDS events (SNAEs, retrospectively collected in BICOMBO). We used exact statistics for relative difference in proportions (RD), and ANOVA for differences between means. Difference was for ABC/3TC minus TDF/FTC. Results: There was no signifi cant difference between arms in VF (RD% 0.7 95%CI -3.4, 4.8). Change from baseline in CD4 was of marginal signifi cance (ITT 0.16 cells/mL 95%CI 0.0, 0.32). Mean change in HDL, LDL, total cholesterol triglycerides were signifi cantly greater in the ABC/3TC arm (p <0.01 for all), there was no difference in total cholesterol:HDL ratio (0.11 95%CI -0.16, 0.29). There was a greater proportion of SNAEs in the ABC/3TC arm (relative difference 3.8%, 95%CI 0.1, 7.6) primarily arising from the STEAL study. Conclusions: In a switch study setting ABC/3TC based therapy was virologically non-inferior over 96 weeks to TDF/FTC based therapy. Lipid markers were generally elevated in the ABC/3TC arm.

Published
2010

29. Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Author

Martínez, E, primary, Arranz, JA, additional, Podzamczer, D, additional, Lonca, M, additional, Sanz, J, additional, Barragán, P, additional, Knobel, H, additional, Ribera, E, additional, Gutierrez, F, additional, Valero, S, additional, Clotet, B, additional, Dalmau, D, additional, Segura, F, additional, Arribas, JR, additional, Barrufet, P, additional, Santos, I, additional, Payeras, A, additional, de Lazzari, E, additional, Pich, J, additional, and Gatell, J, additional

Published
2010
Full Text
View/download PDF

31. Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results

Author

Mallolas, J, primary, Podzamczer, D, additional, Domingo, P, additional, Echeverría, P, additional, Ribera, E, additional, Gutierrez, F, additional, Knobel, H, additional, Cosín, J, additional, Ferrer, E, additional, Arranz, JA, additional, Roca, V, additional, Pich, J, additional, de Lazzari, E, additional, and Gatell, JM, additional

Published
2008
Full Text
View/download PDF

32. P1915 Immunological reconstitution in severely immunosuppressed antiretroviral-naïve patients (<100 CD4+T cells/mm 3) using a non–nucleoside reverse transcriptase inhibitor–based or boosted protease inhibitor–based ART regimen:3–year results

Author

Miro, J.M., primary, Pich, J., additional, Domingo, P., additional, Podzamczer, D., additional, Arribas, J.R., additional, Ribera, E., additional, Arrizabalaga, J., additional, Lonca, M., additional, De Lazzari, E., additional, and Plana, M., additional

Published
2007
Full Text
View/download PDF

34. Relapses Contribute Significantly to the Risk of Plasmodium vivax Infection and Disease in Papua New Guinean Children 1-5 Years of Age.

Author

Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, Del Portillo HA, Siba P, Alonso PL, Bassat Q, and Mueller I

Subjects
MALARIA prevention, DRUG therapy for malaria, COMBINATION drug therapy, TIME, MALARIA, DISEASE relapse, PAPUA New Guineans, ANTIMALARIALS, PRIMAQUINE
Abstract

Background. Plasmodium vivax forms long-lasting hypnozoites in the liver. How much they contribute to the burden of P. vivax malaria in children living in highly endemic areas is unknown. Methods. In this study, 433 Papua New Guinean children aged 1-5 years were Randomized to receive artesunate (7 days) plus primaquine (14 days), artesunate alone or no treatment and followed up actively for recurrent Plasmodium infections and disease for 40 weeks. Results. Treatment with artesunate-primaquine reduced the risk of P. vivax episodes by 28% (P = .042) and 33% (P = .015) compared with the artesunate and control arms, respectively. A significant reduction was observed only in the first 3 months of follow-up (artesunate-primaquine vs control, -58% [P = .004]; artesunate-primaquine vs artesunate, -49% [P = .031]) with little difference thereafter. Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P. vivax reinfections by 44% (P < .001) and 67% (P < .001), respectively. Whereas primaquine treatment did not change the risk of reinfection with Plasmodium falciparum, fewer P. falciparum clinical episodes were observed in the artesunate-primaquine arm. Conclusions. Hypnozoites are an important source of P. vivax infection and contribute substantially to the high burden of P. vivax disease observed in young Papua New Guinean children. Even in highly endemic areas with a high risk of reinfection, antihypnozoite treatment should be given to all cases with parasitologically confirmed P. vivax infections. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

36. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles

Author

De Lazzari E, A. Moreno, Mauri E, Ignasi Anguera, Xavier Claramonte, del Rio A, M. Azqueta, Matínez-Lacasa X, Miró Jm, Quaglio G, Francesc Marco, Manuel Almela, Omar Sued, José M. Gatell, María J. Jiménez-Expósito, García-de la María C, Natividad Benito, C.A. Mestres, Gumá, and Universitat de Barcelona

Subjects
Adult, Male, Pacemaker, Artificial, medicine.medical_specialty, Prosthesis-Related Infections, Staphylococcus lugdunensis, Cohort Studies, Mitral valve, Humans, Medicine, Endocarditis, Staphylococcal infections, Prospective Studies, Abscess, Prospective cohort study, Aged, Ultrasonography, biology, business.industry, Mortality rate, Infeccions per estafilococs, Electronic Pages, Cardiac Pacing, Artificial, Endocarditis, Bacterial, Middle Aged, Staphylococcal Infections, medicine.disease, biology.organism_classification, Survival Analysis, Anti-Bacterial Agents, Surgery, Treatment Outcome, medicine.anatomical_structure, Estudi de casos, Embolism, Heart Valve Prosthesis, Infective endocarditis, Female, Case studies, Cardiology and Cardiovascular Medicine, business
Abstract

Objective: To evaluate the incidence and the clinical and echocardiographic features of infective endocarditis (IE) caused by Staphylococcus lugdunensis and to identify the prognostic factors of surgery and mortality in this disease. Design: Prospective cohort study. Setting: Study at two centres (a tertiary care centre and a community hospital). Patients: 10 patients with IE caused by S lugdunensis in 912 consecutive patients with IE between 1990 and 2003. Methods: Prospective study of consecutive patients carried out by the multidisciplinary team for diagnosis and treatment of IE from the study institutions. English, French, and Spanish literature was searched by computer under the terms “endocarditis” and “Staphylococcus lugdunensis” published between 1989 and December 2003. Main outcome measures: Patient characteristics, echocardiographic findings, required surgery, and prognostic factors of mortality in left sided cases of IE. Results: 10 cases of IE caused by S lugdunensis were identified at our institutions, representing 0.8% (four of 467), 1.5% (two of 135), and 7.8% (four of 51) of cases of native valve, prosthetic valve, and pacemaker lead endocarditis in the non-drug misusers. Native valve IE was present in four patients (two aortic, one mitral, and one pulmonary), prosthetic valve aortic IE in two patients, and pacemaker lead IE in the other four patients. All patients with left sided IE had serious complications (heart failure, periannular abscess formation, or shock) requiring surgery in 60% (three of five patients) of cases with an overall mortality rate of 80% (four of five patients). All patients with pacemaker IE underwent combined medical treatment and surgery, and mortality was 25% (one patient). In total 59 cases of IE caused by S lugdunensis were identified in a review of the literature. The combined analysis of these 69 cases showed that native valve IE (53 patients, 77%) is characterised by mitral valve involvement and frequent complications such as heart failure, abscess formation, and embolism. Surgery was needed in 51% of cases and mortality was 42%. Prosthetic valve endocarditis (nine of 60, 13%) predominated in the aortic position and was associated with abscess formation, required surgery, and high mortality (78%). Pacemaker lead IE (seven of 69, 10%) is associated with a better prognosis when antibiotic treatment is combined with surgery. Conclusions: S lugdunensis IE is an uncommon cause of IE, involving mainly native left sided valves, and it is characterised by an aggressive clinical course. Mortality in left sided native valve IE is high but the prognosis has improved in recent years. Surgery has improved survival in left sided IE and, therefore, early surgery should always be considered. Prosthetic valve S lugdunensis IE carries an ominous prognosis.

37. Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/ emtricitabine (TDF/FTC): 3-year results of the BICOMBO study.

Author

Martínez, E., Arranz, J. A., Podzamczer, D., Lonca, M., Sanz, J., Barragán, P., Knobel, H., Ribera, E., Gutierrez, F., Valero, S., Clotet, B., Dalmau, D., Segura, F., Arribas, J. R., Barrufet, P., Santos, I., Payeras, A., de Lazzari, E., Pich, J., and Gatell, J.

Subjects
HIV-positive persons, ABACAVIR-lamivudine (Drug)
Abstract

An abstract of the article "Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/ emtricitabine (TDF/FTC): 3-year results of the BICOMBO study," by E. Martínez and colleagues is presented.

Published
2010
Full Text
View/download PDF

39. Infective Endocarditis in Patients on Chronic Hemodialysis

Author

Juan M. Pericàs, Jaume Llopis, Maria Jesús Jiménez-Exposito, Wissam M. Kourany, Benito Almirante, Giampiero Carosi, Emanuele Durante-Mangoni, Claudio Querido Fortes, Efthymia Giannitsioti, Stamatios Lerakis, Rodrigo Montagna-Mella, Juan Ambrosioni, Ru-San Tan, Carlos A. Mestres, Dannah Wray, Orathai Pachirat, Asuncion Moreno, Vivian H. Chu, Elisa de Lazzari, Vance G. Fowler, Jose M. Miró, Liliana Clara, Marisa Sanchez, José Casabé, Claudia Cortes, Francisco Nacinovich, Pablo Fernandez Oses, Ricardo Ronderos, Adriana Sucari, Jorge Thierer, Javier Altclas, Silvia Kogan, Denis Spelman, Eugene Athan, Owen Harris, Karina Kennedy, Ren Tan, David Gordon, Lito Papanicolas, Tony Korman, Despina Kotsanas, Robyn Dever, Phillip Jones, Pam Konecny, Richard Lawrence, David Rees, Suzanne Ryan, Michael P. Feneley, John Harkness, Jeffrey Post, Porl Reinbott, Rainer Gattringer, Franz Wiesbauer, Adriana Ribas Andrade, Ana Cláudia Passos de Brito, Armenio Costa Guimarães, Max Grinberg, Alfredo José Mansur, Rinaldo Focaccia Siciliano, Tania Mara Varejao Strabelli, Marcelo Luiz Campos Vieira, Regina Aparecida de Medeiros Tranchesi, Marcelo Goulart Paiva, Auristela de Oliveira Ramos, Clara Weksler, Giovanna Ferraiuoli, Wilma Golebiovski, Cristiane Lamas, James A. Karlowsky, Yoav Keynan, Andrew M. Morris, Ethan Rubinstein, Sandra Braun Jones, Patricia Garcia, M. Cereceda, Alberto Fica, Rodrigo Montagna Mella, Ricardo Fernandez, Liliana Franco, Javier Gonzalez, Astrid Natalia Jaramillo, Bruno Barsic, Suzana Bukovski, Vladimir Krajinovic, Ana Pangercic, Igor Rudez, Josip Vincelj, Tomas Freiberger, Jiri Pol, Barbora Zaloudikova, Zainab Ashour, Amani El Kholy, Marwa Mishaal, Dina Osama, Hussien Rizk, Neijla Aissa, Corentine Alauzet, Francois Alla, CHU Catherine Campagnac, Thanh Doco-Lecompte, Christine Selton-Suty, Jean-Paul Casalta, Pierre-Edouard Fournier, Gilbert Habib, Didier Raoult, Franck Thuny, Francois Delahaye, Armelle Delahaye, Francois Vandenesch, Erwan Donal, Pierre Yves Donnio, Erwan Flecher, Christian Michelet, Matthieu Revest, Pierre Tattevin, Florent Chevalier, Antoine Jeu, Jean Paul Rémadi, Dan Rusinaru, Christophe Tribouilloy, Yvette Bernard, Catherine Chirouze, Bruno Hoen, Joel Leroy, Patrick Plesiat, Christoph Naber, Carl Neuerburg, Bahram Mazaheri, Carl Neuerburg Sophia Athanasia, Ioannis Deliolanis, Helen Giamarellou, Tsaganos Thomas, Elena Mylona, Olga Paniara, Konstantinos Papanicolaou, John Pyros, Athanasios Skoutelis, Konstantinos Papanikolaou, Gautam Sharma, Johnson Francis, Lathi Nair, Vinod Thomas, Krishnan Venugopal, Margaret M. Hannan, John P. Hurley, Maor Wanounou, Dan Gilon, Sarah Israel, Maya Korem, Jacob Strahilevitz, Domenico Iossa, Serena Orlando, Maria Paola Ursi, Pia Clara Pafundi, Fabiana D’Amico, Mariano Bernardo, Susanna Cuccurullo, Giovanni Dialetto, Franco Enrico Covino, Sabrina Manduca, Alessandro Della Corte, Marisa De Feo, Marie Françoise Tripodi, Enrico Cecchi, Francesco De Rosa, Davide Forno, Massimo Imazio, Rita Trinchero, Paolo Grossi, Mariangela Lattanzio, Antonio Toniolo, Antonio Goglio, Annibale Raglio, Veronica Ravasio, Marco Rizzi, Fredy Suter, Silvia Magri, Liana Signorini, Zeina Kanafani, Souha S. Kanj, Ahmad Sharif-Yakan, Imran Abidin, Syahidah Syed Tamin, Eduardo Rivera Martínez, Gabriel Israel Soto Nieto, Jan T.M. van der Meer, Stephen Chambers, David Holland, Arthur Morris, Nigel Raymond, Kerry Read, David R. Murdoch, Stefan Dragulescu, Adina Ionac, Cristian Mornos, O.M. Butkevich, Natalia Chipigina, Ozerecky Kirill, Kulichenko Vadim, Tatiana Vinogradova, Jameela Edathodu, Magid Halim, Yee-Yun Liew, Tatjana Lejko-Zupanc, Mateja Logar, Manica Mueller-Premru, Patrick Commerford, Anita Commerford, Eduan Deetlefs, Cass Hansa, Mpiko Ntsekhe, Manel Almela, Manuel Azqueta, Merce Brunet, Pedro Castro, Elisa De Lazzari, Carlos Falces, David Fuster, Guillermina Fita, Cristina Garcia- de- la- Maria, Javier Garcia-Gonzalez, Jose M. Gatell, Francesc Marco, José M. Miró, José Ortiz, Salvador Ninot, J. Carlos Paré, Juan M. Pericas, Eduard Quintana, Jose Ramirez, Irene Rovira, Elena Sandoval, Marta Sitges, Adrian Tellez, José M. Tolosana, Barbara Vidal, Jordi Vila, Ignasi Anguera, Bernat Font, Joan Raimon Guma, Javier Bermejo, Emilio Bouza, Miguel Angel Garcia Fernández, Victor Gonzalez-Ramallo, Mercedes Marín, Patricia Muñoz, Miguel Pedromingo, Jorge Roda, Marta Rodríguez-Créixems, Jorge Solis, Nuria Fernandez-Hidalgo, Pilar Tornos, Arístides de Alarcón, Ricardo Parra, Eric Alestig, Magnus Johansson, Lars Olaison, Ulrika Snygg-Martin, Pimchitra Pachirat, Burabha Pussadhamma, Vichai Senthong, Anna Casey, Tom Elliott, Peter Lambert, Richard Watkin, Christina Eyton, John L. Klein, Suzanne Bradley, Carol Kauffman, Roger Bedimo, G. Ralph Corey, Anna Lisa Crowley, Pamela Douglas, Laura Drew, Thomas Holland, Tahaniyat Lalani, Daniel Mudrick, Zaniab Samad, Daniel Sexton, Martin Stryjewski, Andrew Wang, Christopher W. Woods, Robert Cantey, Lisa Steed, Stuart A. Dickerman, Hector Bonilla, Joseph DiPersio, Sara-Jane Salstrom, John Baddley, Mukesh Patel, Gail Peterson, Amy Stancoven, Donald Levine, Jonathan Riddle, Michael Rybak, Christopher H. Cabell, Pericas, J. M., Llopis, J., Jimenez-Exposito, M. J., Kourany, W. M., Almirante, B., Carosi, G., Durante-Mangoni, E., Fortes, C. Q., Giannitsioti, E., Lerakis, S., Montagna-Mella, R., Ambrosioni, J., Tan, R. -S., Mestres, C. A., Wray, D., Pachirat, O., Moreno, A., Chu, V. H., de Lazzari, E., Fowler, V. G., Miro, J. M., Clara, L., Sanchez, M., Casabe, J., Cortes, C., Nacinovich, F., Oses, P. F., Ronderos, R., Sucari, A., Thierer, J., Altclas, J., Kogan, S., Spelman, D., Athan, E., Harris, O., Kennedy, K., Tan, R., Gordon, D., Papanicolas, L., Korman, T., Kotsanas, D., Dever, R., Jones, P., Konecny, P., Lawrence, R., Rees, D., Ryan, S., Feneley, M. P., Harkness, J., Post, J., Reinbott, P., Gattringer, R., Wiesbauer, F., Andrade, A. R., Passos de Brito, A. C., Guimaraes, A. C., Grinberg, M., Mansur, A. J., Siciliano, R. F., Varejao Strabelli, T. M., Campos Vieira, M. L., de Medeiros Tranchesi, R. A., Paiva, M. G., de Oliveira Ramos, A., Weksler, C., Ferraiuoli, G., Golebiovski, W., Lamas, C., Karlowsky, J. A., Keynan, Y., Morris, A. M., Rubinstein, E., Jones, S. B., Garcia, P., Cereceda, M., Fica, A., Mella, R. M., Fernandez, R., Franco, L., Gonzalez, J., Jaramillo, A. N., Barsic, B., Bukovski, S., Krajinovic, V., Pangercic, A., Rudez, I., Vincelj, J., Freiberger, T., Pol, J., Zaloudikova, B., Ashour, Z., El Kholy, A., Mishaal, M., Osama, D., Rizk, H., Aissa, N., Alauzet, C., Alla, F., Campagnac, C. C., Doco-Lecompte, T., Selton-Suty, C., Casalta, J. -P., Fournier, P. -E., Habib, G., Raoult, D., Thuny, F., Delahaye, F., Delahaye, A., Vandenesch, F., Donal, E., Donnio, P. Y., Flecher, E., Michelet, C., Revest, M., Tattevin, P., Chevalier, F., Jeu, A., Remadi, J. P., Rusinaru, D., Tribouilloy, C., Bernard, Y., Chirouze, C., Hoen, B., Leroy, J., Plesiat, P., Naber, C., Neuerburg, C., Mazaheri, B., Sophia Athanasia, C. N., Deliolanis, I., Giamarellou, H., Thomas, T., Mylona, E., Paniara, O., Papanicolaou, K., Pyros, J., Skoutelis, A., Papanikolaou, K., Sharma, G., Francis, J., Nair, L., Thomas, V., Venugopal, K., Hannan, M. M., Hurley, J. P., Wanounou, M., Gilon, D., Israel, S., Korem, M., Strahilevitz, J., Iossa, D., Orlando, S., Ursi, M. P., Pafundi, P. C., D'Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M. F., Cecchi, E., De Rosa, F., Forno, D., Imazio, M., Trinchero, R., Grossi, P., Lattanzio, M., Toniolo, A., Goglio, A., Raglio, A., Ravasio, V., Rizzi, M., Suter, F., Magri, S., Signorini, L., Kanafani, Z., Kanj, S. S., Sharif-Yakan, A., Abidin, I., Tamin, S. S., Martinez, E. R., Soto Nieto, G. I., van der Meer, J. T. M., Chambers, S., Holland, D., Morris, A., Raymond, N., Read, K., Murdoch, D. R., Dragulescu, S., Ionac, A., Mornos, C., Butkevich, O. M., Chipigina, N., Kirill, O., Vadim, K., Vinogradova, T., Edathodu, J., Halim, M., Liew, Y. -Y., Lejko-Zupanc, T., Logar, M., Mueller-Premru, M., Commerford, P., Commerford, A., Deetlefs, E., Hansa, C., Ntsekhe, M., Almela, M., Azqueta, M., Brunet, M., Castro, P., Falces, C., Fuster, D., Fita, G., Garcia- de- la- Maria, C., Garcia-Gonzalez, J., Gatell, J. M., Marco, F., Ortiz, J., Ninot, S., Pare, J. C., Quintana, E., Ramirez, J., Rovira, I., Sandoval, E., Sitges, M., Tellez, A., Tolosana, J. M., Vidal, B., Vila, J., Anguera, I., Font, B., Guma, J. R., Bermejo, J., Bouza, E., Garcia Fernandez, M. A., Gonzalez-Ramallo, V., Marin, M., Munoz, P., Pedromingo, M., Roda, J., Rodriguez-Creixems, M., Solis, J., Fernandez-Hidalgo, N., Tornos, P., de Alarcon, A., Parra, R., Alestig, E., Johansson, M., Olaison, L., Snygg-Martin, U., Pachirat, P., Pussadhamma, B., Senthong, V., Casey, A., Elliott, T., Lambert, P., Watkin, R., Eyton, C., Klein, J. L., Bradley, S., Kauffman, C., Bedimo, R., Corey, G. R., Crowley, A. L., Douglas, P., Drew, L., Holland, T., Lalani, T., Mudrick, D., Samad, Z., Sexton, D., Stryjewski, M., Wang, A., Woods, C. W., Cantey, R., Steed, L., Dickerman, S. A., Bonilla, H., Dipersio, J., Salstrom, S. -J., Baddley, J., Patel, M., Peterson, G., Stancoven, A., Levine, D., Riddle, J., Rybak, M., Cabell, C. H., Bristol-Myers Squibb Company, Vall d'Hebron University Hospital [Barcelona], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Laboratoire Chrono-environnement (UMR 6249) (LCE)

Subjects
Male, relapses, medicine.medical_treatment, infective endocarditi, 030204 cardiovascular system & hematology, Kidney Failure, Cohort Studies, Catheters, Indwelling, 0302 clinical medicine, Surgical, Epidemiology, cardiac surgery, enterococci, hemodialysis, infective endocarditis, Staphylococcus aureus, Aged, Anti-Bacterial Agents, Arteriovenous Shunt, Surgical, Cardiac Surgical Procedures, Endocarditis, Female, Humans, Kidney Failure, Chronic, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Renal Dialysis, Staphylococcal Infections, 030212 general & internal medicine, Chronic, Prospective cohort study, health care economics and organizations, relapse, Arteriovenous Shunt, 3. Good health, Cardiac surgery, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Indwelling, Infective endocarditis, Hemodialysis, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Catheters, education, 03 medical and health sciences, Internal medicine, medicine, business.industry, medicine.disease, hemodialysi, Etiology, Complication, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background - Infective endocarditis (IE) is a common and serious complication in patients receiving chronic hemodialysis (HD). Objectives - This study sought to investigate whether there are significant differences in complications, cardiac surgery, relapses, and mortality between IE cases in HD and non-HD patients. Methods - Prospective cohort study (International Collaboration on Endocarditis databases, encompassing 7,715 IE episodes from 2000 to 2006 and from 2008 to 2012). Descriptive analysis of baseline characteristics, epidemiological and etiological features, complications and outcomes, and their comparison between HD and non-HD patients was performed. Risk factors for major embolic events, cardiac surgery, relapses, and in-hospital and 6-month mortality were investigated in HD-patients using multivariable logistic regression. Results - A total of 6,691 patients were included and 553 (8.3%) received HD. North America had a higher HD-IE proportion than the other regions. The predominant microorganism was Staphylococcus aureus (47.8%), followed by enterococci (15.4%). Both in-hospital and 6-month mortality were significantly higher in HD versus non-HD-IE patients (30.4% vs. 17% and 39.8% vs. 20.7%, respectively; p

Published
2021

40. A global metagenomic map of urban microbiomes and antimicrobial resistance

Author

Nadine Farhat, Tomoki Takeda, Astred Castro, Ken McGrath, Khaliun Sanchir, Iman Hajirasouliha, Eunice So, Laraib Zafar, Diana N. Nunes, Harun Mustafa, Amy Zhang, Priscilla Lisboa, Christian Schori, Marisano James, Jasna Chalangal, Sebastien Halary, Shahryar Rana, Yunmi Lee, Oli Schacher, Liliana Godoy, David A. Coil, Phanthira Pugdeethosal, Michelle D. Williams, German Marchandon, Angela Cantillo, Naoya Takahashi, Christopher Mozsary, Juana Gonzalez, Patrick K. H. Lee, Gerardo de Lamotte, Alessandro Robertiello, Steven Du, Fabienne Velter, Stefan G. Stark, Miguel Carbajo, Vincent Matthys, David A. Westfall, Julia Boeri, Irène Mauricette Mendy, Jonathan Cedillo, Francesco Oteri, Robert W. Crawford, Takayuki Ito, Tina Wunderlin, Maureen Muscat, David Paez-Espino, Carmen Urgiles, Aida Nesimi, Steffen Schaaf, Adan Ramirez-Rojas, Kunihiko Miyake, Christopher E. Mason, Anais Cardenas, Sharah Islam, Diego Benítez, Melissa Pool Pizzi, Kianna Ciaramella, Ciro Borrelli, Riham Islam, Dorottya Nagy-Szakal, Abd-Manaaf Bakere, Ait-hamlat Adel, Olha Lakhneko, Badamnyambuu Iderzorig, Ana Valeria Castro, Adam Phillips, Robert A. Petit, Flavia Corsi, Romain Conte, Krista Ryon, Soojin Jang, Joseph Benson, Fernanda de Souza Gomes Kehdy, Cindy Wang, Nicole Mathews, Jenn-Wei Chen, Rachel Paras, Paulina Pastuszek, Abigail Lyons, Paul Roldán, Muntaha Munia, Pierre Nicolas, Cassie L. Ettinger, Kyrylo Pyrshev, Katterinne N. Mendez, Eduardo Castro-Nallar, Valeriia Dotsenko, Michelle Tuz, Krizzy Mallari, Eileen Png, Yuya Sonohara, Tanja Miketic, Stéphane Delmas, Shu Zhang, Masaki Sato, Yuanting Zheng, Jifeng Zhu, Roland Häusler, Lucie Bittner, Savlatjon Rahmatulloev, Jonathan Foox, Bruno D'Alessandro, Alketa Plaku, Faisal Alquaddoomi, Yang Zhang, Kern Rei Chng, Juliana Lago, Allaeddine Chettouh, Tamera Henry, Houtan Noushmehr, Tranette Gregory, Sara Abdul Majid, Frank J. Kelly, Benjamin Pulatov, Laurie Casalot, Takema Kajita, Lennard Epping, Thais Fernanda Bartelli, Eftar Moniruzzaman, Renee Vivancos-Koopman, Thirumalaisamy P. Velavan, Tracy W. Liu, Yelyzaveta Tymoshenko, Alma Plaku, Nika Gurianova, Ambar Mendez, Anna Tomaselli, Sonia Dorado, Donato Giovannelli, Hira Choudhry, Synti Ng, Sheelta S. Kumar, Jennifer Q. Lu, Weijun Liang, Ellen Koag, Dennis Gankin, Maria João Amorim, Gwenola Simon, Kiyoshi Suganuma, Mikhail Karasikov, Christos A. Ouzounis, Madelyn May, Eran Elhaik, Stephan Ossowski, Kevin Bolzli, Matthew Arthur, Yuya Oto, Jananan Pathmanathan, Salah Mahmoud, Kou Takahashi, Brunna Marques, Kelly French, Felipe Sepúlveda, Shusei Yoshikawa, Paulo Thiago de Souza Santos, Andrew N. Gray, Juliana S Bernardes, Felipe Segato, Björn Brindefalk, George C. Yeh, Jhovana L. Velasco Flores, Jill Sullivan, Silva Baburyan, Denisse Flores, Russell Y. Neches, Sabrina Persaud, Rasheena Wright, Takumi Togashi, Verónica Antelo, Nao Kato, Skye Felice, Tatjana Mustac, Daisy Donnellan, Katerine Carrillo, Anna Litskevitch, Catalina García, Sota Ito, Naya Eady, Andrew Wan, Irene Meng, Sophie Guasco, Danilo Ercolini, Francesca De Filippis, Vincent Lemaire, Luice Fan, Lothar H. Wieler, Mariia Rybak, Jorge Sanchez, Jonathan S. Gootenberg, Itsuki Tomita, Maritza S Mosella, Laura Garcia, Natalka Makogon, Daisy Cheung, Hitler Francois Vasquez Arevalo, Freddy Asenjo, Gabriela P. Branco, Erika Cifuentes, Chloé Dequeker, Aspassia D. Chatziefthimiou, Alexis Terrero, Roy Meoded, Isabelle de Oliveira Moraes, Shaleni K. Singh, Orgil-Erdene Molomjamts, Karishma Miah, Laurent David, Wolfgang Haehr, Dao Phuong Giang, Romain Lannes, Prashanthi Ratnanandan, Ryota Yamanaka, Riccardo Vicedomini, Sadaf Ayaz, Oluwatosin M. Osuolale, Laura E. Vann, Gregory Chem, Andrea Gonzalez, Aszia Burrell, Ariel Chernomoretz, Sakura Ishizuka, Michelle Rivera, Avigdor Nosrati, Michelle B. Chen, Juliette Auvinet, Nils Ordioni, Tomoro Warashina, Guillaume Blanc, Tomislav Ivankovic, Christina Black, Lauren E. Hittle, David Hess-Homeier, Michael Kozhar, Hamood Suliman, Karobi Moitra, Saher Rahiel, Spyridon Gkotzis, Jenny Arevalo, Shaikh B. Iqbal, Beth Mutai, Mohammed Mohsin, Scott Tighe, Sylvie Collin, Yoshitaka Saito, Wayne Menary, Youping Deng, Lucy Lee, Esmeralda Jiminez, Ayuki Watanabe, Nikos C. Kyrpides, Natasha Mohan, Angelika Pupiec, Dedan Githae, Simone Cawthorne, Jonathan A. Eisen, Tomoki Iwashiro, Chiaki Homma, Thomas Saw Aung, Laura Molina, Marcus H. Y. Leung, Ophélie Da Silva, Yan Ling Wong, Hosna Noorzi, Mario Moreno, Alina Butova, Leming Shi, Brian W. Wong, Sarah S. Jackson, Moses Lin, Annabelle Meagher, Pujita Das, Catherine Burke, Mitsuki Ota, Maria Domenica Moccia, Nicolas Sprinsky, Catherine E. Pugh, David C. Green, Fazlina Fauzi, Erdenetsetseg Batdelger, Annie Geiger, Valeria Ventorino, Tolulope Oluwadare, Delisia Cuebas, Catalina Truong, Leonardo Posada, Michael Angelov, Tathiane M. Malta, Amanda Ng, Francesca Nadalin, Arya Hawkins-Zafarnia, Yuh Shiwa, Athena Mitsios, Milton Ozório Moraes, Manolo Laiola, Kalyn Ali, Jaden J.A. Hastings, Ikuto Saito, Maheen Shakil, Chisato Suzuki, Elena M. Vayndorf, Hubert Rehrauer, Ajay Menon, Kaitlan Russell, Aliyah Shari, Rebecca Smith, Gregorio Iraola, Max Priestman, Alan Briones, Silver A. Wolf, Camila Gonzalez-Poblete, Eleonora De Lazzari, Shirley Chiu, Michelle Ki, Irene Hoxie, Marianne Jaubert, Ayantu Jinfessa, Ryan J. King, Nghiem Xuan Hoan, Jalia Bynoe, Jacob Friedman, Aneisa Ramcharan, Pablo Fresia, Cristina Muñoz, Muhammad Afaq, Anyi Tang, Médine Benchouaia, Isabella Kuniko T. Takenaka, Anastasia Chasapi, Areeg Naeem, Hannah Benisty, Cecilia N. Cossio, Nathalie Hüsser, Mahfuza Sabina, Thais S. Sabedot, JoAnn Jacobs, Camila P. E. de Souza, Manuela Oliveira, Jean-Pierre Bouly, Mariko Usui, Wilson Miranda, Natalia Marciniak, Hiram Caballero, Samuel Weekes, Alexandra B. Graf, Emily Leong, Tatyana Nikolayeva, Dominique Thomas, Charlotte Greselle, Cecilia Salazar, Sreya Ray Chaudhuri, Kevin Becher, Sandra Roth, Ryusei Miura, Kari Oline Bøifot, Dimitri Manoir, Oliver Toth, Chandrima Bhattacharya, Manuel Perez, Isha Lamba, Takafumi Tsurumaki, Timothy D. Read, Anna-Lena M. Schinke, Ryan Sankar, Le Huu Song, Narasimha Rao Nedunuri, Emmanuel Dias-Neto, Ana Flávia Costa, Adiell Melamed, Christelle Desnues, Natalie R. Davidson, Aaron E. Darling, Hyung Jun Kim, Josephine Galipon, Jacqueline Orrego, Dimitar Vassilev, Michael Huber, Nur Hazlin Hazrin-Chong, Gaston H. Gonnet, Kaymisha Knights, Osman U. Sezerman, Dmitry Meleshko, Eunice Thambiraja, Jingcheng Yang, Aubin Fleiss, Gloria Nguyen, Katelyn Jackson, Nuria Aventin, Stephanie L. Hyland, Andrea Hässig, Catharine Aquino, Simona Lysakova, Israel O. Osuolale, Kasia Sluzek, Rania Siam, Alina Frolova, Samuel Hernandez, Yui Him Lo, Bazartseren Boldgiv, Ben Young, Maryna Korshevniuk, Majelia Ampadu, Yuk Man Tang, Amanda L. Muehlbauer, Sade Thomas, Gabriel Figueroa, Alexis Rivera, Lisbeth Pineda, Alexandra Dutan, Jennifer M. Tran, Chris K. Deng, Vedbar S. Khadka, Paola Florez de Sessions, Elizabeth Humphries, Hugues Richard, Hiba Naveed, Nora C. Toussaint, Mahshid Khavari, Maria del Mar Vivanco Ruiz, Antonin Thiébaut, Nicolás Rascovan, Marius Dybwad, Orhan Özcan, Lawrence Kwong, David Danko, Shaira Khan, Andrea Tassinari, Silvia Beurmann, Tsoi Ying Lai, Nanami Kubota, Tieliu Shi, Diana Chicas, Evan E. Afshin, Hirokazu Yano, Jonas Krebs, Mayuko Nakagawa, Hyun Jung Lee, Irene González Navarrete, Rachid Ounit, Lucia E. Alvarado-Arnez, Masaki Nasu, Allison Chan, Harilanto Andrianjakarivony, Jennifer Amachee, Mahdi Taye, Wan Chiew Ng, Kathryn O’Brien, Shino Ishikawa, Tristan Bitard-Feildel, Sora Takagi, Felix Hartkopf, Niamh B. O’Hara, Marcos A. S. Fonseca, Subhamitra Pakrashi, Amrit Kaur, Eva Hell, Patricia Vera-Wolf, Naimah Munim, Luiza Ferreira de Araújo, Mizuki Igarashi, Brianna Pompa-Hogan, Alessandra Carbone, Anne-Sophie Benoiston, Eric Helfrich, Michael A. Suarez-Villamil, Omar O. Abudayyeh, Natasha Abdullah, Jaime J. Fuentes, Juan Carlos Forero, Tetiana Yeskova, Denis Bertrand, Sambhawa Priya, Denisse Maldonado, Agier Nicolas, Ana Valeria B Castro, Starr Chatziefthimiou, André Kahles, Aaishah Francis, Fernanda Arredondo, Emilio Tarcitano, Irvind Buttar, Alex Alexiev, Jennifer Molinet, Sarah Shalaby, Itunu A. Oluwadare, Jason Sperry, Katrin Bakhl, Ana M. Cañas, Sofia Ahsanuddin, Miar Elaskandrany, Elodie Laine, Sven Bönigk, Johannes Werner, Stephen Eduard Boja Ruiz, Gargi Dayama, Paulina Buczansla, Brandon Valentine, Bharath Prithiviraj, Toni Bode, Stas Zubenko, Jake Cohen, Guilllaume Jospin, Zulena Saravi, Per O. Ljungdahl, Inderjit Kaur, Mauricio Moldes, Giuseppe KoLoMonaco, Denise Syndercombe Court, Sonia Bouchard, Sonia Losim, Sookwon Moon, Heba Shaaban, Suraj Patel, Sibo Zhu, Sarh Aly, Arif Asyraf Md Supie, LaShonda Dorsey, Juan Guerra, François Baudon, Rantimi A. Olawoyin, Alexia Bordigoni, Iqra Faiz, Mathilde Garcia, Gabriella Mason-Buck, María Gabriela Portilla, Niranjan Nagarajan, Fumie Takahara, Nancy Merino, Watson Andrew, Gina Kim, Yuma Sato, Hyenah Shim, Marie-Laure Jerier, Affifah Saadah Ahmad Kassim, Katerina Kuchin, Daniel Butler, Paweł P. Łabaj, Nadezhda Kobko-Litskevitch, Emmanuel F. Mongodin, Yuto Togashi, Paula Rodríguez, Pilar Lopez Hernandez, Xiaoqing Chen, Maria A. Sierra, Olga Nikolayeva, Manon Loubens, Colleen Conger, Hikaru Shirahata, Chenhao Li, Timothy Donahoe, Youngja Park, Lucia Elena Alvarado Arnez, Salama Chaker, Francisco Chavez, Alessandra Breschi, Jorge L. Sanchez, Kaung Myat San, Nayra Aguilar Rojas, Marcos Abraao, Kai Sasaki, Bryan Nazario, Olena Yemets, Klas I. Udekwu, Lynn M. Schriml, Anisia Peters, Aliaksei Holik, Mark Hernandez, Emile Faure, Malay Bhattacharyya, Josef W. Moser, Núria Andreu Somavilla, María Mercedes Zambrano, Kannan Rajendran, Gabriela E. Albuquerque, Tao Qing, Kazutoshi Tsuda, Ymke De Jong, Princess Osma, Mayra Arauco Livia, Javier Quilez Oliete, Carl Chrispin, Hyun Woo Joo, Ingrid Lafontaine, Nala An, Seisuke Sato, Felipe Segato Dezem, Andrew Maltez Thomas, Alexandre Desert, Xiao Wen Cai, O. Osuolale, Jun Wu, Coral Pardo-Esté, Courtney Robinson, Yuri Matsuzaki, Marina Nieto-Caballero, Cem Meydan, Ralph Schlapbach, Mark Menor, Sofia Castro, Rachel Kwong, Brittany Blyther, Olexandr Lykhenko, Jason R. Schriml, Christian Brion, Jenessa Orpilla, Juan A. Ugalde, Elsy Mankah Ngwa, Álvaro Aranguren, Lauren Mak, Matías Giménez, Ashanti Narce, Torsten Semmler, Stefan I. Tsonev, Abdollahi Nika, Katherine E. Dahlhausen, Monika Devi, Gunnar Rätsch, Oasima Muner, Carla Bello, Muhammad Al-Fath Amran, Anyelic Rosario, Melissa Ortega, Andrea Patrignani, Ante Peros, Elias McComb, Ryo Sato, Ireen Alam, Clara N. Dias, Soma Tanaka, Dayana Calderon, Ran Blekhman, Mathilde Mignotte, Alicia Boyd, Jochen Hecht, Thomas Neff, Xinzhao Tong, Josue Alicea, Kiara Olmeda, Sonia Marinovic, Carme Arnan, Kohei Ito, Samantha L. Goldman, Marianna S. Serpa, Renee Richer, Kaisei Sato, Jordana M. Silva, Akash Keluth Chavan, Sangwan Kim, Laís Pereira Ferreira, Sophie Vacant, Nowshin Sayara, Haruo Suzuki, Madeline Leahy, Juan C. Severyn, Sierra Vincent, Masaru Tomita, Maliha Mamun, Lucinda B. Davenport, Gabriella Oken, Dagmara Lewandowska, Gustavo Adolfo Malca Salas, Andrii Kuklin, Tyler Wong, Charlie Feigin, Eric Minwei Liu, Sonia L. Ghose, Daniela Bezdan, Antonietta La Storia, Juan P. Escalera-Antezana, Nuno Rufino de Sousa, Samuel M. Gerner, Weill Cornell Medicine [New York], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Genome Institute of Singapore (GIS), Centre for Genomic Regulation [Barcelona] (CRG), Universitat Pompeu Fabra [Barcelona] (UPF)-Centro Nacional de Analisis Genomico [Barcelona] (CNAG), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Lawrence Berkeley National Laboratory [Berkeley] (LBNL), AUTRES, Massachusetts Institute of Technology (MIT), Indian Statistical Institute [Kolkata], University of Minnesota System, Universidad Andrés Bello [Santiago] (UNAB), California State University [Sacramento], University of Naples Federico II, University of Hawaii, Institut méditerranéen d'océanologie (MIO), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Toulon (UTLN), Medical Genomics Group, University College of London [London] (UCL)-UCL Cancer Institute, Norwegian Defence Research Establishment (FFI), Lund University [Lund], Institute of Molecular Biology and Genetics of National Academy of Sciences of Ukraine, University of Vienna [Vienna], King‘s College London, University of Colorado [Boulder], Institut Pasteur de Montevideo, Réseau International des Instituts Pasteur (RIIP), Institut Pasteur Korea - Institut Pasteur de Corée, Fudan University [Shanghai], City University of Hong Kong [Hong Kong] (CUHK), Stockholm University, University of Maryland School of Medicine, University of Maryland System, Fundação Oswaldo Cruz (FIOCRUZ), University of São Paulo (USP), Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Barcelona Institute of Science and Technology (BIST), Elizade University, Acibadem Mehmet Ali Aydınlar University, Paléogénomique microbienne - Microbial paleogenomics, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU), Robert Koch Institute [Berlin] (RKI), East China Normal University [Shangaï] (ECNU), Cairo University, Vietnamese-German Center for Medical Research, Keio University, Université du Vermont, Universidad del Desarrollo, University of Sofia, University of Alaska [Fairbanks] (UAF), Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Corporación Corpogen-Research Center, Biologie Computationnelle et Quantitative = Laboratory of Computational and Quantitative Biology (LCQB), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Weill Cornell Medicine [Cornell University], Cornell University [New York], University of Naples Federico II = Università degli studi di Napoli Federico II, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), Universidade de São Paulo = University of São Paulo (USP), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Софийски университет = Sofia University, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universidad Andrés Bello - UNAB (CHILE), Acibadem University Dspace, Danko, D., Bezdan, D., Afshin, E. E., Ahsanuddin, S., Bhattacharya, C., Butler, D. J., Chng, K. R., Donnellan, D., Hecht, J., Jackson, K., Kuchin, K., Karasikov, M., Lyons, A., Mak, L., Meleshko, D., Mustafa, H., Mutai, B., Neches, R. Y., Ng, A., Nikolayeva, O., Nikolayeva, T., Png, E., Ryon, K. A., Sanchez, J. L., Shaaban, H., Sierra, M. A., Thomas, D., Young, B., Abudayyeh, O. O., Alicea, J., Bhattacharyya, M., Blekhman, R., Castro-Nallar, E., Canas, A. M., Chatziefthimiou, A. D., Crawford, R. W., De Filippis, F., Deng, Y., Desnues, C., Dias-Neto, E., Dybwad, M., Elhaik, E., Ercolini, D., Frolova, A., Gankin, D., Gootenberg, J. S., Graf, A. B., Green, D. C., Hajirasouliha, I., Hastings, J. J. A., Hernandez, M., Iraola, G., Jang, S., Kahles, A., Kelly, F. J., Knights, K., Kyrpides, N. C., Labaj, P. P., Lee, P. K. H., Leung, M. H. Y., Ljungdahl, P. O., Mason-Buck, G., Mcgrath, K., Meydan, C., Mongodin, E. F., Moraes, M. O., Nagarajan, N., Nieto-Caballero, M., Noushmehr, H., Oliveira, M., Ossowski, S., Osuolale, O. O., Ozcan, O., Paez-Espino, D., Rascovan, N., Richard, H., Ratsch, G., Schriml, L. M., Semmler, T., Sezerman, O. U., Shi, L., Shi, T., Siam, R., Song, L. H., Suzuki, H., Court, D. S., Tighe, S. W., Tong, X., Udekwu, K. I., Ugalde, J. A., Valentine, B., Vassilev, D. I., Vayndorf, E. M., Velavan, T. P., Wu, J., Zambrano, M. M., Zhu, J., Zhu, S., Mason, C. E., Abdullah, N., Abraao, M., Adel, A. -H., Afaq, M., Al-Quaddoomi, F. S., Alam, I., Albuquerque, G. E., Alexiev, A., Ali, K., Alvarado-Arnez, L. E., Aly, S., Amachee, J., Amorim, M. G., Ampadu, M., Amran, M. A. -F., An, N., Andrew, W., Andrianjakarivony, H., Angelov, M., Antelo, V., Aquino, C., Aranguren, A., Araujo, L. F., Vasquez Arevalo, H. F., Arevalo, J., Arnan, C., Alvarado Arnez, L. E., Arredondo, F., Arthur, M., Asenjo, F., Aung, T. S., Auvinet, J., Aventin, N., Ayaz, S., Baburyan, S., Bakere, A. -M., Bakhl, K., Bartelli, T. F., Batdelger, E., Baudon, F., Becher, K., Bello, C., Benchouaia, M., Benisty, H., Benoiston, A. -S., Benson, J., Benitez, D., Bernardes, J., Bertrand, D., Beurmann, S., Bitard-Feildel, T., Bittner, L., Black, C., Blanc, G., Blyther, B., Bode, T., Boeri, J., Boldgiv, B., Bolzli, K., Bordigoni, A., Borrelli, C., Bouchard, S., Bouly, J. -P., Boyd, A., Branco, G. P., Breschi, A., Brindefalk, B., Brion, C., Briones, A., Buczansla, P., Burke, C. M., Burrell, A., Butova, A., Buttar, I., Bynoe, J., Bonigk, S., Boifot, K. O., Caballero, H., Cai, X. W., Calderon, D., Cantillo, A., Carbajo, M., Carbone, A., Cardenas, A., Carrillo, K., Casalot, L., Castro, S., Castro, A. V., Castro, A., Castro, A. V. B., Cawthorne, S., Cedillo, J., Chaker, S., Chalangal, J., Chan, A., Chasapi, A. I., Chatziefthimiou, S., Chaudhuri, S. R., Chavan, A. K., Chavez, F., Chem, G., Chen, X., Chen, M., Chen, J. -W., Chernomoretz, A., Chettouh, A., Cheung, D., Chicas, D., Chiu, S., Choudhry, H., Chrispin, C., Ciaramella, K., Cifuentes, E., Cohen, J., Coil, D. A., Collin, S., Conger, C., Conte, R., Corsi, F., Cossio, C. N., Costa, A. F., Cuebas, D., D'Alessandro, B., Dahlhausen, K. E., Darling, A. E., Das, P., Davenport, L. B., David, L., Davidson, N. R., Dayama, G., Delmas, S., Deng, C. K., Dequeker, C., Desert, A., Devi, M., Dezem, F. S., Dias, C. N., Donahoe, T. R., Dorado, S., Dorsey, L., Dotsenko, V., Du, S., Dutan, A., Eady, N., Eisen, J. A., Elaskandrany, M., Epping, L., Escalera-Antezana, J. P., Ettinger, C. L., Faiz, I., Fan, L., Farhat, N., Faure, E., Fauzi, F., Feigin, C., Felice, S., Ferreira, L. P., Figueroa, G., Fleiss, A., Flores, D., Velasco Flores, J. L., Fonseca, M. A. S., Foox, J., Forero, J. C., Francis, A., French, K., Fresia, P., Friedman, J., Fuentes, J. J., Galipon, J., Garcia, M., Garcia, L., Garcia, C., Geiger, A., Gerner, S. M., Ghose, S. L., Giang, D. P., Gimenez, M., Giovannelli, D., Githae, D., Gkotzis, S., Godoy, L., Goldman, S., Gonnet, G. H., Gonzalez, J., Gonzalez, A., Gonzalez-Poblete, C., Gray, A., Gregory, T., Greselle, C., Guasco, S., Guerra, J., Gurianova, N., Haehr, W., Halary, S., Hartkopf, F., Hawkins-Zafarnia, A., Hazrin-Chong, N. H., Helfrich, E., Hell, E., Henry, T., Hernandez, S., Hernandez, P. L., Hess-Homeier, D., Hittle, L. E., Hoan, N. X., Holik, A., Homma, C., Hoxie, I., Huber, M., Humphries, E., Hyland, S., Hassig, A., Hausler, R., Husser, N., Petit, R. A., Iderzorig, B., Igarashi, M., Iqbal, S. B., Ishikawa, S., Ishizuka, S., Islam, S., Islam, R., Ito, K., Ito, S., Ito, T., Ivankovic, T., Iwashiro, T., Jackson, S., Jacobs, J., James, M., Jaubert, M., Jerier, M. -L., Jiminez, E., Jinfessa, A., De Jong, Y., Joo, H. W., Jospin, G., Kajita, T., Ahmad Kassim, A. S., Kato, N., Kaur, A., Kaur, I., de Souza Gomes Kehdy, F., Khadka, V. S., Khan, S., Khavari, M., Ki, M., Kim, G., Kim, H. J., Kim, S., King, R. J., Kolomonaco, G., Koag, E., Kobko-Litskevitch, N., Korshevniuk, M., Kozhar, M., Krebs, J., Kubota, N., Kuklin, A., Kumar, S. S., Kwong, R., Kwong, L., Lafontaine, I., Lago, J., Lai, T. Y., Laine, E., Laiola, M., Lakhneko, O., Lamba, I., de Lamotte, G., Lannes, R., De Lazzari, E., Leahy, M., Lee, H., Lee, Y., Lee, L., Lemaire, V., Leong, E., Lewandowska, D., Li, C., Liang, W., Lin, M., Lisboa, P., Litskevitch, A., Liu, E. M., Liu, T., Livia, M. A., Lo, Y. H., Losim, S., Loubens, M., Lu, J., Lykhenko, O., Lysakova, S., Mahmoud, S., Majid, S. A., Makogon, N., Maldonado, D., Mallari, K., Malta, T. M., Mamun, M., Manoir, D., Marchandon, G., Marciniak, N., Marinovic, S., Marques, B., Mathews, N., Matsuzaki, Y., Matthys, V., May, M., Mccomb, E., Meagher, A., Melamed, A., Menary, W., Mendez, K. N., Mendez, A., Mendy, I. M., Meng, I., Menon, A., Menor, M., Meoded, R., Merino, N., Miah, K., Mignotte, M., Miketic, T., Miranda, W., Mitsios, A., Miura, R., Miyake, K., Moccia, M. D., Mohan, N., Mohsin, M., Moitra, K., Moldes, M., Molina, L., Molinet, J., Molomjamts, O. -E., Moniruzzaman, E., Moon, S., de Oliveira Moraes, I., Moreno, M., Mosella, M. S., Moser, J. W., Mozsary, C., Muehlbauer, A. L., Muner, O., Munia, M., Munim, N., Muscat, M., Mustac, T., Munoz, C., Nadalin, F., Naeem, A., Nagy-Szakal, D., Nakagawa, M., Narce, A., Nasu, M., Navarrete, I. G., Naveed, H., Nazario, B., Nedunuri, N. R., Neff, T., Nesimi, A., Ng, W. C., Ng, S., Nguyen, G., Ngwa, E., Nicolas, A., Nicolas, P., Nika, A., Noorzi, H., Nosrati, A., Nunes, D. N., O'Brien, K., O'Hara, N. B., Oken, G., Olawoyin, R. A., Oliete, J. Q., Olmeda, K., Oluwadare, T., Oluwadare, I. A., Ordioni, N., Orpilla, J., Orrego, J., Ortega, M., Osma, P., Osuolale, I. O., Osuolale, O. M., Ota, M., Oteri, F., Oto, Y., Ounit, R., Ouzounis, C. A., Pakrashi, S., Paras, R., Pardo-Este, C., Park, Y. -J., Pastuszek, P., Patel, S., Pathmanathan, J., Patrignani, A., Perez, M., Peros, A., Persaud, S., Peters, A., Phillips, A., Pineda, L., Pizzi, M. P., Plaku, A., Pompa-Hogan, B., Portilla, M. G., Posada, L., Priestman, M., Prithiviraj, B., Priya, S., Pugdeethosal, P., Pugh, C. E., Pulatov, B., Pupiec, A., Pyrshev, K., Qing, T., Rahiel, S., Rahmatulloev, S., Rajendran, K., Ramcharan, A., Ramirez-Rojas, A., Rana, S., Ratnanandan, P., Read, T. D., Rehrauer, H., Richer, R., Rivera, A., Rivera, M., Robertiello, A., Robinson, C., Rodriguez, P., Rojas, N. A., Roldan, P., Rosario, A., Roth, S., Ruiz, M., Boja Ruiz, S. E., Russell, K., Rybak, M., Sabedot, T. S., Sabina, M., Saito, I., Saito, Y., Malca Salas, G. A., Salazar, C., San, K. M., Sanchez, J., Sanchir, K., Sankar, R., de Souza Santos, P. T., Saravi, Z., Sasaki, K., Sato, Y., Sato, M., Sato, S., Sato, R., Sato, K., Sayara, N., Schaaf, S., Schacher, O., Schinke, A. -L. M., Schlapbach, R., Schori, C., Schriml, J. R., Segato, F., Sepulveda, F., Serpa, M. S., De Sessions, P. F., Severyn, J. C., Shakil, M., Shalaby, S., Shari, A., Shim, H., Shirahata, H., Shiwa, Y., Da Silva, O., Silva, J. M., Simon, G., Singh, S. K., Sluzek, K., Smith, R., So, E., Andreu Somavilla, N., Sonohara, Y., Rufino de Sousa, N., Souza, C., Sperry, J., Sprinsky, N., Stark, S. G., La Storia, A., Suganuma, K., Suliman, H., Sullivan, J., Supie, A. A. M., Suzuki, C., Takagi, S., Takahara, F., Takahashi, N., Takahashi, K., Takeda, T., Takenaka, I. K., Tanaka, S., Tang, A., Man Tang, Y., Tarcitano, E., Tassinari, A., Taye, M., Terrero, A., Thambiraja, E., Thiebaut, A., Thomas, S., Thomas, A. M., Togashi, Y., Togashi, T., Tomaselli, A., Tomita, M., Tomita, I., Toth, O., Toussaint, N. C., Tran, J. M., Truong, C., Tsonev, S. I., Tsuda, K., Tsurumaki, T., Tuz, M., Tymoshenko, Y., Urgiles, C., Usui, M., Vacant, S., Vann, L. E., Velter, F., Ventorino, V., Vera-Wolf, P., Vicedomini, R., Suarez-Villamil, M. A., Vincent, S., Vivancos-Koopman, R., Wan, A., Wang, C., Warashina, T., Watanabe, A., Weekes, S., Werner, J., Westfall, D., Wieler, L. H., Williams, M., Wolf, S. A., Wong, B., Wong, Y. L., Wong, T., Wright, R., Wunderlin, T., Yamanaka, R., Yang, J., Yano, H., Yeh, G. C., Yemets, O., Yeskova, T., Yoshikawa, S., Zafar, L., Zhang, Y., Zhang, S., Zhang, A., Zheng, Y., and Zubenko, S.

Subjects
Urban Population, Drug Resistance, Sequence assembly, Microbiologia, microbiome, global health, computer.software_genre, Medical and Health Sciences, shotgun sequencing, BGC, 0302 clinical medicine, Databases, Genetic, 11. Sustainability, Global health, AMR, 11 Medical and Health Sciences, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, built environment, metagenome, antimicrobial resistance, NGS, de novo assembly, biology, Shotgun sequencing, Microbiota, built Environment, Bacterial, Biodiversity, Biological Sciences, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infection, Biotechnology, Geospatial analysis, [SDV.BID]Life Sciences [q-bio]/Biodiversity, Article, General Biochemistry, Genetics and Molecular Biology, Databases, 03 medical and health sciences, Antibiotic resistance, Genetic, Drug Resistance, Bacterial, International MetaSUB Consortium, Genetics, Humans, Microbiome, 030304 developmental biology, Human Genome, 06 Biological Sciences, 15. Life on land, biology.organism_classification, Resistènica als medicaments antiinfecciosos, SAÚDE PÚBLICA, Genòmica, 13. Climate action, Evolutionary biology, Metagenomics, Antimicrobial Resistance, [SDE.BE]Environmental Sciences/Biodiversity and Ecology, computer, 030217 neurology & neurosurgery, Archaea, Developmental Biology
Abstract

Summary We present a global atlas of 4,728 metagenomic samples from mass-transit systems in 60 cities over 3 years, representing the first systematic, worldwide catalog of the urban microbial ecosystem. This atlas provides an annotated, geospatial profile of microbial strains, functional characteristics, antimicrobial resistance (AMR) markers, and genetic elements, including 10,928 viruses, 1,302 bacteria, 2 archaea, and 838,532 CRISPR arrays not found in reference databases. We identified 4,246 known species of urban microorganisms and a consistent set of 31 species found in 97% of samples that were distinct from human commensal organisms. Profiles of AMR genes varied widely in type and density across cities. Cities showed distinct microbial taxonomic signatures that were driven by climate and geographic differences. These results constitute a high-resolution global metagenomic atlas that enables discovery of organisms and genes, highlights potential public health and forensic applications, and provides a culture-independent view of AMR burden in cities., Graphical abstract, Highlights • Cities possess a consistent “core” set of non-human microbes • Urban microbiomes echo important features of cities and city-life • Antimicrobial resistance genes are widespread in cities • Cities contain many novel bacterial and viral species, This systematic, worldwide catalog of urban microbiomes represents a metagenomic atlas important for understanding the ecology, virulence, and antibiotic resistance of city-specific microbial communities.

Published
2021

43. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study

Author

Javier Murillas, M. Cervantes, José Mallolas, S. López-Calvo, Josep M. Guardiola, Montserrat Laguno, Jordi Navarro, Carmen Cifuentes, Anna Cruceta, Ana Carrero, M.A. Von Wichmann, Juan A. Pineda, María Martínez-Rebollar, Elisabeth Deig, J.L. Gómez-Sirvent, Antoni Jou, E. Van den Eynde, A. Tapiz, Marisa Montes, J.D. Ruiz-Mesa, S. Veloso, E de Lazzari, [Laguno, M.] Hosp Clin Barcelona, IDIBAPS, Villarroel 170, Barcelona, Spain, [Martinez-Rebollar, M.] Hosp Clin Barcelona, IDIBAPS, Villarroel 170, Barcelona, Spain, [Cruceta, A.] Hosp Clin Barcelona, IDIBAPS, Villarroel 170, Barcelona, Spain, [de lazzari, E.] Hosp Clin Barcelona, IDIBAPS, Villarroel 170, Barcelona, Spain, [Mallolas, J.] Hosp Clin Barcelona, IDIBAPS, Villarroel 170, Barcelona, Spain, [Von Wichmann, M. A.] Hosp Univ Donostia, Donostia San Sebastian, Spain, [Van den Eynde, E.] Hosp Univ Bellvitge, Bellvitge, Spain, [Navarro, J.] Hosital Univ Vall dHebron, Barcelona, Spain, [Cifuentes, C.] Hosp Son Llatzer, Palma De Mallorca, Spain, [Murillas, J.] Hosp Son Espases, Palma De Mallorca, Spain, [Veloso, S.] Hosp Univ Joan XXIII, Tarragona, Spain, [Guardiola, J. M.] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Jou, A.] Hosp Badalona Germans Trias & Pujol, Badalona, Spain, [Gomez-Sirvent, J. L.] Hosp Univ Canarias, Tenerife, Spain, [Cervantes, M.] Corp Sanitaria Parc Tauli, Sabadell, Spain, [Pineda, J. A.] Hosp Univ Valme, Seville, Spain, [Lopez-Calvo, S.] Hosp Univ A Coruna, La Coruna, Spain, [Carrero, A.] Hosp Univ Gregorio Maranon, Madrid, Spain, [Montes, M. L.] Hosp Univ La Paz, Madrid, Spain, [Deig, E.] Hosp Granollers, Granollers, Spain, [Tapiz, A.] Fundacio Althaia, Manresa, Spain, [Ruiz-Mesa, J. D.] Hosp Reg, Malaga, Spain, Merck: BOC-HIV Study, and Instituto de Salud Carlos III, Ministerio Economia y Competitividad

Subjects
Peptidasas, Male, Cirrhosis, HIV Infections, interferón alfa, HCV genotype 1, Hepacivirus, Phase-2 trial, Oral inhibitors, Gastroenterology, Telaprevir, Polyethylene Glycols, 0302 clinical medicine, Pegylated interferon, estudios prospectivos, ribavirina, PEG-IFN/RBV plus BOC therapy, Clinical endpoint, VIH-VHC, Prospective Studies, mediana edad, Boceprevir, PEG-IFN therapy, Coinfection, farmacoterapia, virus diseases, General Medicine, adulto, Genotype 1, Interferon, retratamiento, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Safety, Microbiology (medical), medicine.medical_specialty, 616.9, Genotype, Proline, Antiviral Agents, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Drug Therapy, Humans, proteínas recombinantes, Pacients, Inhibidores orales, Adverse effect, HIV–HCV experienced patients, medicine.disease, digestive system diseases, Discontinuation, chemistry, proteínas víricas no estructurales, genotipo, Teràpia PEG-IFN, glicoles de polietileno, antivíricos, humanos, Interferó, Viral Nonstructural Proteins, medicine.disease_cause, Genotipo 1, chemistry.chemical_compound, prolina, PEG-IFN/RBV + BOC therapy, 030212 general & internal medicine, coinfección, resultado del tratamiento, Cohort, HIV-HCV experienced patients, Middle Aged, Hepatitis C, Recombinant Proteins, Infectious Diseases, Treatment Outcome, Retreatment, Pacientes, Female, Terapia PEG-IFN, medicine.drug, Adult, Patients, Hepatitis C virus, Coinfected patients, Interferon-alpha-2b, Re-treatment, Genotip 1, Internal medicine, Ribavirin, medicine, Triple-therapy, lcsh:RC109-216, PEG-IFN/RBV+BOC therapy, Espanya, business.industry, Interferon-alpha, Proteasa, Protease, Surgery, Inhibidors orals, RBV + BOC, Spain, infecciones por VIH, business
Abstract

Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferonfree therapies are not available yet., Funded by Merck: BOC-HIV Study.Maria Martinez-Rebollar is funded by a grant Sara Borrell, CM13-00123, from Instituto de Salud Carlos III, Ministerio Economia y Competitividad. - Other authors declare no other conflict of interest.

Published
2016

44. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study

Author

Murdoch , David R, Corey , G Ralph, Hoen , Bruno, Miró , José M, Fowler , Vance G, Bayer , Arnold S, Karchmer , Adolf W, Olaison , Lars, Pappas , Paul A, Moreillon , Philippe, Chambers , Stephen T, Chu , Vivian H, Falcó , Vicenç, Holland , David J, Jones , Philip, Klein , John L, Raymond , Nigel J, Read , Kerry M, Tripodi , Marie Francoise, Utili , Riccardo, Wang , Andrew, Woods , Christopher W, Cabell , Christopher H, Renseigné , Non, International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators, Gordon, D., Devi, U., Spelman, D., van der Meer, J.T., Kauffman, C., Bradley, S., Armstrong, W., Giannitsioti, E., Giamarellou, H., Lerakis, S., del Rio, A., Moreno, A., Mestres, C.A., Ninot, C.A., Pare, C., de la Maria, C.G., Armero, Y., de Lazzari, E., Marco, F., Gatell, J.M., Almela, M., Azqueta, M., Sitges, M., Claramonte, X., Jiménez-Expósito, M.J., de Benito, N., Ramirez, J., Perez, N., Miro, J.M., Almirante, B., Fernandez-Hidalgo, N., de Vera, P.R., Tornos, P., Falco, V., Sidani, N., Kanj-Sharara, S., Kanafani, Z., Raglio, A., Goglio, A., Gnecchi, F., Suter, F., Valsecchi, G., Rizzi, M., Ravasio, V., Hoen, B., Chirouze, C., Leroy, J., Plesiat, P., Bernard, Y., Casey, A., Lambert, P., Watkin, R., Elliott, T., Patel, M., Dismukes, W., Pan, A., Caros, G., Mathiron, A.B., Tribouilloy, C., Goissen, T., Delahaye, A., Delahaye, F., Vandenesch, F., Vizzotti, C., Nacinovich, F.M., Marin, M., Trivi, M., Lombardero, M., Cortes, C., Casabé, J.H., Altclas, J., Kogan, S., Clara, L., Sanchez, M., Commerford, A., Hansa, C., Deetlefs, E., Ntsekhe, M., Commerford, P., Wray, D., Steed, L.L., Church, P., Cantey, R., Morris, A., Holland, D.J., Murdoch, D.R., Chambers, S.T., Read, K.M., Raymond, N.J., Lang, S., Kotsanas, D., Korman, T.M., Peterson, G., Purcell, J., Southern, P.M., Shah, M., Bedimo, R., Reddy, A., Levine, D., Dhar, G., Hanlon-Feeney, A., Hannan, M., Kelly, S., Wang, A., Cabell, C.H., Woods, C.W., Sexton, D.J., Benjamin, D.J., McDonald, J.R., Federspiel, J., Engemann, J.J., Reller, B., Drew, L., Caram, L.B., Stryjewski, M., Morpeth, S., Lalani, T., Fowler, V.G., Chu, V.H., Mazaheri, B., Neuerburg, C., Naber, C., Athan, E., Henry, M., Harris, O., Alestig, E., Olaison, L., Wikstrom, L., Snygg-Martin, U., Francis, J., Venugopal, K., Nair, L., Thomas, V., Chaiworramukkun, J., Pachirat, O., Chetchotisakd, P., Suwanich, T., Kamarulzaman, A., Tamin, S.S., Premru, M.M., Logar, M., Lejko-Zupanc, T., Orezzi, C., Klein, J.L., Bouz, E., Rodríguez-Créixems, M., Marín, M., Fernández, M., Muñoz, P., Fernández, R., Ramallo, V., Raoult, D., Thuny, F., Habib, G., Casalta, J.P., Fournier, P.E., Chipigina, N., Kirill, O., Vinogradova, T., Kulichenko, V.P., Butkevich, O.M., Lion, C., Selton-Suty, C., Coyard, H., Doco-Lecompte, T., Iarussi, D., Durante-Mangoni, E., Ragone, E., Dialetto, G., Tripodi, M.F., Utili, R., Casillo, R., Kumar, A.S., Sharma, G., Dickerman, S.A., Street, A., Eisen, D.P., McBryde, E.S., Grigg, L., Abrutyn, E., Michelet, C., Tattevin, P., Donnio, P.Y., Fortes, C.Q., Edathodu, J., Al-Hegelan, M., Font, B., Anguera, I., Guma, J.R., Cereceda, M., Oyonarte, M.J., Mella, R.M., Garcia, P., Jones, S.B., Ramos, A.I., Paiva, M.G., Tranchesi, R.A., Woon, L.L., Lum, L.N., Tan, R.S., Rees, D., Kornecny, P., Lawrence, R., Dever, R., Post, J., Jones, P., Ryan, S., Harkness, J., Feneley, M., Rubinstein, E., Strahilewitz, J., Ionac, A., Mornos, C., Dragulescu, S., Forno, D., Cecchi, E., De Rosa, F., Imazio, M., Trinchero, R., Wiesbauer, F., Gattringer, R., Deans, G., Andrasevic, A.T., Barsic, B., Klinar, I., Vincelj, J., Bukovski, S., Krajinovic, V., Stafford, J., Baloch, K., Pappas, P.A., Redick, T., Harding, T., Karchmer, A.W., Bayer, A.S., Corey, R., Moreillon, P., Durack, D.T., Eykyn, S., Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Murdoch, D., Corey, G., Miro', J., Fowler, V. J., Bayer, A., Karchmer, A., Pappas, P., Chambers, S., Chu, V., Falco', V., Holland, D., Klein, J., Raymond, N., Read, K., Tripodi, M. F., Utili, Riccardo, Woods, C., Cabell, C., AII - Amsterdam institute for Infection and Immunity, Infectious diseases, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Male, MESH: Endocarditis, MESH : Aged, MESH : Prospective Studies, 030204 cardiovascular system & hematology, endocarditi, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Mitral valve, MESH: Staphylococcus aureus, MESH : Female, Prospective Studies, Prospective cohort study, Abscess, MESH: Aged, Adult, Aged, Endocarditis/microbiology, Endocarditis/mortality, Endocarditis/therapy, Female, Humans, Middle Aged, Staphylococcal Infections/microbiology, Staphylococcus aureus/isolation & purification, endocarditis, hospital mortality, 0303 health sciences, MESH: Middle Aged, Endocarditis, MESH : Staphylococcus aureus, Staphylococcal Infections, MESH : Adult, MESH : Endocarditis, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, medicine.anatomical_structure, Infective endocarditis, epidemiology, Staphylococcus aureus, medicine.medical_specialty, complications, MESH : Male, MESH: Staphylococcal Infections, Staphylococcal infections, Article, 03 medical and health sciences, Endocarditis, clinical presentattion, S. aureus, Internal medicine, Internal Medicine, medicine, MESH : Middle Aged, staphylococci, MESH: Humans, 030306 microbiology, business.industry, clinical presentattion, MESH : Humans, MESH: Adult, Odds ratio, S. aureus, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Prospective Studies, Surgery, Etiology, MESH : Staphylococcal Infections, business, MESH: Female
Abstract

International audience; BACKGROUND: We sought to provide a contemporary picture of the presentation, etiology, and outcome of infective endocarditis (IE) in a large patient cohort from multiple locations worldwide. METHODS: Prospective cohort study of 2781 adults with definite IE who were admitted to 58 hospitals in 25 countries from June 1, 2000, through September 1, 2005. RESULTS: The median age of the cohort was 57.9 (interquartile range, 43.2-71.8) years, and 72.1% had native valve IE. Most patients (77.0%) presented early in the disease (

Published
2009

46. Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.

Author

Laguno M, de Lazzari E, Berrocal L, Inciarte A, Martínez-Rebollar M, de la Mora L, Torres B, Gonzalez-Cordón A, Chivite I, Foncillas A, Calvo J, Sempere A, Ambrosioni J, Blanco JL, Miro JM, Mallolas J, and Martínez E

Abstract

Background: Liver steatosis (LS) and liver fibrosis (LF) can increase the risk of cardiovascular disease in people with HIV, but their prevalence and associated factors are poorly understood. This study aimed to assess the prevalence of and factors associated with LS and LF in a large cohort of people with HIV., Methods: We conducted a cross-sectional study of consecutive people with HIV attending the Clinic of Barcelona from September 2022 to September 2023, excluding those with chronic B or/and C hepatitis virus coinfection. LS was assessed using the Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI), and LF was assessed using the Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS), Fibrosis-4 score (FIB-4), and the European AIDS Clinical Society (EACS) algorithm in both the whole cohort (cohort 1) and in a specific cohort more susceptible to liver disease (cohort 2). We identified independent variables associated with LS and LF using logistic regression., Results: Cohort 1 included 4664 people with HIV; 76% and 37% of them had available HSI and FLI data, LS was present in 28% and 19%, respectively. LF risk was present in 1%, 2%, and 1% of people with HIV according to NFS, FIB-4, and EACS algorithm scores, respectively. Cohort 2 included 1345 people with HIV; 60% and 30% of them had available HSI and FLI data, LS affected 55% and 43% and LF 2%, 5%, or 3%, respectively. Factors associated with LS included current CD4 cell count, diabetes, and hypertension, whereas LF was associated with previous exposure to dideoxynucleoside drugs and current CD4 to LF. Current integrase strand transfer inhibitor (INSTI) therapy appeared protective for LF in cohort 1., Conclusions: In this study, one in four people with HIV had LS, and the prevalence rose to one in two in those with cardiovascular risk factors. The prevalence of LF was low, but it should be considered in older people with HIV with low CD4 counts or high aspartate transaminase levels. A possible protective effect from INSTIs deserves further investigation., (© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)

Published
2024
Full Text
View/download PDF

47. Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV: A cross-sectional population-based study.

Author

de Lazzari E, Nomah DK, Blanco JL, Rico N, Filella X, Egri N, Ruiz R, Marcos MA, Mosquera MDM, Alcamí J, Sánchez-Palomino S, Bruguera A, Hurtado C, Rovira C, Ambrosioni J, Chivite I, González-Cordón A, Inciarte A, Laguno M, Martínez-Rebollar M, de la Mora L, Torres B, Díaz Y, Martínez E, Mallolas J, and Miro JM

Abstract

Objectives: The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study aimed to assess the SARS-CoV-2 prevalence and associated risk factors among unvaccinated PWH, and to evaluate the impact of tenofovir., Methods: We conducted as a cross-sectional study between November 2020 and May 2021. Plasma samples from 4,400 of 5,476 PWH were tested for total antibodies, IgG, IgM, and IgA., Results: Among the participants (median age 48 years, 84% male), 92% had undetectable HIV viral loads and 5% had syphilis. The prevalence of SARS-CoV-2 infection was 18% (95% CI 17-19), with 1,180 individuals showing antibodies (IgG 13%, IgA 10%, IgM 11%). Of those seropositive for SARS-CoV-2, 67.5% were asymptomatic, 29% had mild disease, and 3.5% had severe/critical conditions. Risk factors included younger age, being female, men who have sex with men (MSM) status, non-European origin, and a history of syphilis. Neither antiretrovirals nor tenofovir provided protection against SARS-CoV-2 infection or COVID-19 disease., Conclusion: Ongoing surveillance and tailored interventions are crucial for at-risk PWH amid evolving SARS-CoV-2 variants. Tenofovir did not prevent SARS-CoV-2 infection or COVID-19., Competing Interests: Declaration of competing interests JMM has received consulting honoraria and/or research grants from Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, all outside the current work. DKN received consultation fees from OPIS and is an employee of Aetion Iberia, both outside the current work. All other authors declared no conflicts., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2024
Full Text
View/download PDF

48. Epidemiological changes and outcomes of people living with HIV admitted to the intensive care unit: a 14-year retrospective study.

Author

Martínez E, Foncillas A, Téllez A, Fernández S, Martínez-Nadal G, Rico V, Tomé A, Ugarte A, Rinaudo M, Berrocal L, De Lazzari E, Miró JM, Nicolás JM, Mallolas J, De la Mora L, and Castro P

Abstract

Purposes: Since 2016, the World Health Organization has recommended universal antiretroviral therapy (ART) for all people living with Human Immunodeficiency Virus (PLHIV). This recommendation may have influenced the characteristics and outcomes of PLHIV admitted to the Intensive Care Unit (ICU). This study aims to identify changes in the epidemiological and clinical characteristics of PLHIV admitted to the ICU, and their short- and medium-term outcomes before and after the implementation of universal ART (periods 2006-2015 and 2016-2019)., Methods: This retrospective, observational, single-center study included all adult PLHIV admitted to the ICU of a University Hospital in Barcelona from 2006 to 2019., Results: The study included 502 admissions involving 428 patients, predominantly men (75%) with a median (P25-P75) age of 47.5 years (39.7-53.9). Ninety-one percent were diagnosed with HIV before admission, with 82% under ART and 60% admitted from the emergency department. In 2016-2019, there were more patients on ART pre-admission, reduced needs for invasive mechanical ventilation (IMV) and fewer in-ICU complications. ICU mortality was also lower (14% vs 7%). Predictors of in-ICU mortality included acquired immunodeficiency syndrome defining event (ADE)-related admissions, ICU complications, higher SOFA scores, IMV and renal replacement therapy (RRT) requirement. ART use during ICU admission was protective. Higher SOFA scores, admission from hospital wards, and more comorbidities predicted one-year mortality., Conclusions: The in-ICU mortality of critically ill PLHIV has decreased in recent years, likely due to changes in patient characteristics. Pre- and ICU admission features remain the primary predictors of short- and medium-term outcomes., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

49. Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study.

Author

Ugarte A, De La Mora L, De Lazzari E, Chivite I, Fernández E, Inciarte A, Laguno M, Ambrosioni J, Solbes E, Berrocal L, González-Cordón A, Martínez-Rebollar M, Foncillas A, Calvo J, Blanco JL, Martínez E, Mallolas J, and Torres B

Subjects
Humans, Male, Adult, Prospective Studies, Female, Heterocyclic Compounds, 4 or More Rings administration & dosage, Heterocyclic Compounds, 4 or More Rings therapeutic use, Heterocyclic Compounds, 4 or More Rings adverse effects, Piperazines administration & dosage, Amides administration & dosage, Amides therapeutic use, Adenine analogs & derivatives, Adenine therapeutic use, Adenine administration & dosage, Adenine adverse effects, Drug Combinations, Heterocyclic Compounds, 3-Ring administration & dosage, Heterocyclic Compounds, 3-Ring therapeutic use, Heterocyclic Compounds, 3-Ring adverse effects, Middle Aged, Young Adult, Viral Load drug effects, HIV Infections drug therapy, Tenofovir therapeutic use, Tenofovir administration & dosage, Tenofovir analogs & derivatives, Emtricitabine therapeutic use, Emtricitabine administration & dosage, Anti-HIV Agents therapeutic use, Anti-HIV Agents administration & dosage, Pyridones administration & dosage, Alanine therapeutic use, Alanine administration & dosage
Abstract

Introduction: Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical and ART-related considerations hinder immediate initiation of therapy., Methods: An open-label, single-arm, single-centre 48-week prospective clinical trial involving ART-naïve HIV-diagnosed adults who started bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) within a week from the first hospital visit, before the availability of baseline laboratory and genotype results. The primary aim was to determine the proportion of people with at least one condition that would hinder immediate initiation of any recommended ART regimen other than BIC/FTC/TAF. Clinicaltrials.gov: NCT04416906., Results: We included 100 participants: 79% men, 64% from Latin America, median age 32 years. According to European AIDS Clinical Society (EACS) and US Department of Health and Human Services 2023 guidelines, 11% (95%CI 6; 19) of participants had at least one condition that made any ART different from BIC/FTC/TAF less appropriate for a rapid ART strategy. Seventy-nine percent of the people started BIC/FTC/TAF within the first 48 hours of their first hospital visit. There were 16 early discontinuations (11 lost to follow-up). By week 48, 92% (95%CI 86; 98) of the participants of the ITT population with observed data achieved viral suppression. Eight grade 3-4 adverse events (AEs), five serious AEs and six ART-related AEs were identified. Adherence remained high., Conclusions: BIC/FTC/TAF is an optimal treatment for rapid initiation of ART. However, additional strategies to improve retention in care must be implemented., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

50. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.

Author

Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Blanco JL, Martínez E, Mallolas J, and Ambrosioni J

Subjects
Humans, Drug Combinations, Amides therapeutic use, Piperazines, Pyridones, Adenine analogs & derivatives, Adenine therapeutic use, Adenine adverse effects, Adenine administration & dosage, Treatment Outcome, HIV-1 drug effects, HIV-1 genetics, Retrospective Studies, HIV Infections drug therapy, Tenofovir therapeutic use, Tenofovir administration & dosage, Tenofovir analogs & derivatives, Anti-HIV Agents therapeutic use, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Emtricitabine therapeutic use, Emtricitabine administration & dosage, Heterocyclic Compounds, 4 or More Rings therapeutic use, Heterocyclic Compounds, 4 or More Rings administration & dosage, Heterocyclic Compounds, 4 or More Rings adverse effects, Alanine therapeutic use, Viral Load drug effects, Heterocyclic Compounds, 3-Ring therapeutic use, Heterocyclic Compounds, 3-Ring adverse effects, Heterocyclic Compounds, 3-Ring administration & dosage
Abstract

Background: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is based on the results of robust clinical trials., Objectives: To assess the effectiveness and safety of BIC/FTC/TAF in treatment-naïve (TN) and treatment-experienced (TE) people with HIV using available real-world cohort studies., Methods: Systematic review and meta-analysis of publications and communications identified via Boolean search in Medline, PubMed and Embase, and conference abstracts reporting retrospective real-world use of BIC/FTC/TAF, published until 31 January 2024. The primary endpoint was the proportion of TN and TE people with HIV with viral load (VL) < 50 copies/mL at 48 weeks while on treatment., Results: Of the 38 identified publications and conference abstracts, for the present analysis we included 12 publications (comprising 792 TN and 6732 TE individuals). For the three publications including 507 TN participants reporting the primary outcome, VL suppression was 97% [95% confidence intervals (CI): 89-100]. For the nine publications including 4946 TE participants reporting the primary outcome, VL suppression was 95% (95% CI: 94-96), with suppression >93% in all studies. Total discontinuations at 48 weeks in TE individuals were 3% (95% CI: 2-5), 1% (95% CI: 0-2) due to side effects. A total of four publications with 151 TE individuals with previous presence of M184V substitution were identified, reporting a suppression rate at 48 weeks of 95% (95% CI: 88-100)., Conclusions: Real-world studies demonstrate low discontinuation rates and high rates of virologic suppression in individuals treated with BIC/FTC/TAF, both TN and TE with and without previous detection of M184V substitution., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results